
Claims

1. A compound of formula I-A



I-A

wherein

W^1 represents C-R^{W1} or N;

W^2 represents C-R^{W2} or N;

W^3 represents C-R^{W3} or N;

W^4 represents C-R^{W4} or N;

wherein either none of W^1, W^2, W^3 and W^4 represents N or only one of W^1, W^2, W^3 and W^4 represents N at the same time: and

R^{W1} represents H, C_{1-6}-aliphatic, halogen;

R^{W2} represents H, C_{1-6}-aliphatic; halogen;

R^{W3} represents H, C_{1-6}-aliphatic, -O-C_{1-6}-aliphatic, halogen, -CN, -CH_2-Ar^W or -CH_2-CH_2-Ar^W

R^{W4} represents H, C_{1-6}-aliphatic, halogen;

Z^1 is CH or N;

Z^2 is CR^{Z2} or N;

Z^3 is CR^{Z3} or N;

wherein at least two of Z^1, Z^2 and Z^3 are not N;

R^1 represents Ar^1, $Hetar^1$, Cyc^1, $Hetcyc^1$, L^1-Ar^1, L^1-$Hetar^1$, L^2-Cyc^1, L^2-$Hetcyc^1$, C_{1-8}-aliphatic which is substituted with 1, 2 or 3 halogen which may be the same or different;

R^2 represents -C(=O)-OR^{2a}, -C(=O)-$NR^{2b}R^{2c}$, -$(CH_2)_w$-C(=O)-$NR^{2b}R^{2c}$, -$(CH_2)_x$-NR^{2d}-C(=O)-R^{2e}, -S-R^{2f}, -S(=O)-R^{2f}, -$S(=O)_2$-R^{2g}, -$S(=O)_2$-$NR^{2h}R^{2i}$, -$S(=O)_2$-OH, -S(=O)(=NR^{2j})-OH, -S(=O)(=NR^{2j})-R^{2g}, -

$S(=O)(=NR^{2k})$-$NR^{2l}R^{2m}$, -$P(=O)(OR^{2o})(OR^{2p})$, -$(CH_2)_y$-$NR^{2q}R^{2r}$, -$(CH_2)_z$-NR^{2d}-$S(=O)_2$-R^{2g}, -N=S(=O)-$R^{2s}R^{2t}$, -C(=O)-N=S(=O)-$R^{2s}R^{2t}$, -C(=O)-N=S(=N-R^{2u})-$R^{2s}R^{2t}$, or $Hetcyc^X$;

Ar^W represents phenyl which may be unsubstituted or mono- or di-substituted with independently from each other R^{W11} and/or R^{W12};

R^{Z2} represents H; or forms together with R^2 a divalent radical -$S(=O)_2$-N(H)-C(=O)-;

R^{Z3} represents H or halogen;

R^{2a} represents H, un-substituted or substituted C_{1-8}-aliphatic, aryl, heteroaryl, saturated or partially unsaturated heterocyclyl, or Cat;

Cat represents a monovalent cation;

R^{2b}, R^{2c}, R^{2q}, R^{2r} represent independently from each other H, un-substituted or substituted C_{1-8}-aliphatic including C_{3-7}-cycloaliphatic; or

R^{2b} together with R^{2c} and/or R^{2q} together with R^{2r} form together with the nitrogen atom to which they are attached to an unsubstituted or substituted saturated, partially unsaturated or aromatic heterocycle with 3, 4, 5, 6, 7 ring atoms wherein 1 of said ring atoms is said nitrogen atom and no or one further ring atom is a hetero atom selected from N, O or S and the remaining are carbon atoms; wherein said heterocycle may optionally be fused with $Hetar^Z$; or

one of R^{2b} and R^{2c} represents -OH, -O-C_{1-6}-alkyl, -NH_2, -CN or -$S(=O)_2$-R^{2g}, Ar^2, $Hetar^2$, Cyc^2, $Hetcyc^2$, while the other represents H or un-substituted or substituted C_{1-8}-aliphatic;

R^{2d}, R^{2j}, R^{2k}, R^{2o}, R^{2p} represent independently from each other H, un-substituted or substituted C_{1-8}-aliphatic, heteroaryl;

R^{2e} represents H, halogen, un-substituted or substituted C_{1-8}-aliphatic, aryl, heteroaryl; saturated or partially unsaturated heterocyclyl;

R^{2f}, R^{2g} represent independently from each other un-substituted or substituted C_{1-8}-aliphatic;

R^{2h}, R^{2i} represent independently from each other H, un-substituted or substituted C_{1-8}-aliphatic, aryl, heterocyclyl, heteroaryl; or form together with the nitrogen atom to which they are attached to an unsubstituted or

substituted saturated, partially unsaturated or aromatic heterocycle with 3, 4, 5, 6, 7 ring atoms wherein 1 of said ring atoms is said nitrogen atom and no or one further ring atom is a hetero atom selected from N, O or S and the remaining are carbon atoms;

R^{2l}, R^{2m} represent independently from each other H, un-substituted or substituted C_{1-8}-aliphatic; or form together with the nitrogen atom to which they are attached to an unsubstituted or substituted saturated, partially unsaturated or aromatic heterocycle with 3, 4, 5, 6, 7 ring atoms wherein 1 of said ring atoms is said nitrogen atom and no or one further ring atom is a hetero atom selected from N, O or S and the remaining are carbon atoms;

R^{2s}, R^{2t} represent independently from each other unsubstituted or substituted C_{1-8}-aliphatic; or form together an unsubstituted or substituted divalent C_{3-6}-alkylene radical;

R^{2u} represents hydrogen or unsubstituted or substituted C_{1-6}-aliphatic;

Ar^1 is a mono-, bi- or tricyclic aryl with 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 ring carbon atoms, wherein that aryl may be unsubstituted or substituted with substituents R^{B1}, R^{B2}, R^{B3}, R^{B4}, R^{B5}, R^{B6} and/or R^{B7} which may be the same or different;

$Hetar^1$ is a mono-, bi- or tricyclic heteroaryl with 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 ring atoms wherein 1, 2, 3, 4, 5 of said ring atoms is/are a hetero atom(s) selected from N, O and/or S and the remaining are carbon atoms, wherein that heteroaryl may be unsubstituted or substituted with substituents R^{B1}, R^{B2}, R^{B3}, R^{B4}, R^{B5}, R^{B6} and/or R^{B7} which may be the same or different;

Cyc^1 is a saturated or partially unsaturated, mono-, bi- or tricyclic carbocycle with 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 ring carbon atoms, wherein that carbocycle may be unsubstituted or substituted with R^{B8}, R^{B9}, R^{B10}, R^{B11} R^{B12} and/or R^{B13} which may be the same or different; and wherein that carbocycle may optionally be fused to Ar^X via 2 adjacent ring atoms of said Ar^X and wherein that fused carbocycle may be

unsubstituted or substituted with R^{C1}, R^{C2}, R^{C3}, R^{C4}, R^{C5} and/or R^{C6} which may be the same or different;

$Hetcyc^1$ is a saturated or partially unsaturated, mono-, bi- or tricyclic heterocycle with 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 ring atoms wherein 1, 2, 3, 4, 5 of said ring atoms is/are a hetero atom(s) selected from N, O and/or S and the remaining are carbon atoms, wherein that heterocycle may be unsubstituted or substituted with R^{B8}, R^{B9}, R^{B10}, R^{B11}, R^{B12} and/or R^{B13} which may be the same or different;

L^1 is a divalent radical selected from the group consisting of $-S(=O)_2-$, un-substituted or substituted, straight-chain or branched C_{1-6}-alkylene or C_{1-6}-alkenylene, in both of which one of the carbon units of the alkylene or alkenylene chain may be replaced by -O-;

L^2 is a divalent radical selected from the group consisting of un-substituted or substituted, straight-chain or branched C_{1-6}-alkylene or C_{2-6}-alkenylene, in both of which one of the carbon units of the alkylene or alkenylene chain may be replaced by -O-;

R^{W11}, R^{W12} represent independently from each other halogen or un-substituted or substituted C_{1-6}-aliphatic;

R^{B1}, R^{B2}, R^{B3}, R^{B4}, R^{B5}, R^{B6}, R^{B7} represent independently from each other un-substituted or substituted C_{1-6}-aliphatic, C_{1-6}-aliphatoxy, $-S-C_{1-6}$-aliphatic; halogen, -CN, $-S(=O)-R^{b1}$, $S(=O)_2-R^{b1}$, $-NR^{b2}R^{b3}$, Ar^2, $-CH_2-Ar^2$, $Hetar^2$, Cyc^2, $Hetcyc^2$;

and/or two adjacent R^{B1}, R^{B2}, R^{B3}, R^{B4}, R^{B5}, R^{B6} and/or R^{B7} form together a divalent $-C_{2-4}$-alkylene radical in which one of the alkylene carbon units may be replaced by a carbonyl unit (-C(=O)-), or a divalent $-O-C_{1-3}$-alkylene radical or a divalent $-O-C_{1-3}$-alkylene-O- radical;

R^{b1} represents un-substituted or substituted C_{1-8}-aliphatic;

R^{b2}, R^{b3} represent independently from each other H, un-substituted or substituted C_{1-8}-aliphatic; or

form together with the nitrogen atom to which they are attached to an unsubstituted or substituted saturated, partially unsaturated or aromatic heterocycle with 3, 4, 5, 6, 7 ring atoms wherein 1 of said ring atoms is

said nitrogen atom and no or one further ring atom is a hetero atom selected from N, O or S and the remaining are carbon atoms;

R^{B8}, R^{B9}, R^{B10}, R^{B11}, R^{B12}, R^{B13} represent independently from each other halogen, un-substituted or substituted C_{1-6}-aliphatic, C_{1-6}-aliphatoxy, Ar^Y; and/or

two of R^{B8}, R^{B9}, R^{B10}, R^{B11}, R^{B12}, R^{B13} which are attached to the same carbon atom of said carbocycle or said heterocycle form a divalent oxo (=O) group; and/or

two of R^{B8}, R^{B9}, R^{B10}, R^{B11}, R^{B12}, R^{B13} or four of R^{B8}, R^{B9}, R^{B10}, R^{B11}, R^{B12}, R^{B13} which are attached to the same sulfur atom of said heterocycle form a divalent oxo (=O) group thereby forming either an -S(=O)- or an $-S(=O)_2-$ moiety;

Ar^2 is a mono- or bicyclic aryl with 5, 6, 7, 8, 9, 10 ring carbon atoms, wherein that aryl may be unsubstituted or substituted with substituents R^{D1}, R^{D2}, R^{D3}, R^{D4} and/or R^{D5} which may be the same or different;

$Hetar^2$ is a mono- or bicyclic heteroaryl with 5, 6, 7, 8, 9, 10 ring atoms wherein 1, 2, 3, 4, 5 of said ring atoms is/are a hetero atom(s) selected from N, O and/or S and the remaining are carbon atoms, wherein that heteroaryl may be unsubstituted or substituted with substituents R^{D1}, R^{D2}, R^{D3}, R^{D4} and/or R^{D5} which may be the same or different;

Cyc^2 is a saturated or partially unsaturated monocyclic carbocycle with 3, 4, 5, 6 or 7 ring carbon atoms, wherein that carbocycle may be unsubstituted or substituted with R^{D6}, R^{D7}, R^{D8}, R^{D9} and/or R^{D10} which may be the same or different; wherein that carbocycle may optionally be fused to Ar^Z or $Hetar^Z$ via 2 adjacent ring atoms of said Ar^Z or $Hetar^Z$ and wherein that fused carbocycle may further be unsubstituted or substituted with R^{C1}, R^{C2}, R^{C3}, R^{C4}, R^{C5} and/or R^{C6} which may be the same or different;

$Hetcyc^2$ is a saturated or partially unsaturated, monocyclic heterocycle with 3, 4, 5, 6, 7 ring atoms wherein 1 or 2 of said ring atoms is/are a hetero atom(s) selected from N, O and/or S and the remaining are carbon atoms, wherein that heterocycle may be unsubstituted or substituted with R^{D6},

R^{D7}, R^{D8}, R^{D9} and/or R^{D10} which may be the same or different; wherein that heterocycle may optionally be fused to Ar^Z or $Hetar^Z$ via 2 adjacent ring atoms of said Ar^Z or $Hetar^Z$ and wherein that fused heterocycle may further be unsubstituted or substituted with R^{C1}, R^{C2}, R^{C3}, R^{C4}, R^{C5} and/or R^{C6} which may be the same or different;

Ar^X, Ar^Z are independently from each other an un-substituted or substituted benzo ring;

Ar^Y is an un-substituted or mono- or di-substituted phenyl;

$Hetar^{Y1}$ is a 5 or 6 membered monocyclic heteroaryl wherein 1, 2, 3, 4 ring atoms are hetero atoms selected from N, O and/or S and the remaining are carbon atoms, wherein that heteroaryl may be unsubstituted or substituted with halogen, C_{1-4}-alkyl which may optionally be substituted with OH;

$Hetar^Z$ is an unsubstituted or substituted 5 or 6 membered heteroaryl ring selected from the group consisting of pyrrole, furan, thiophene, pyrazole, imidazole, oxaole, isoxazole, thiazole, oxadiazole, triazole, tetrazole, pyridine, pyrimidine, pyrazine, pyrane;

Cyc^{Y1} is a saturated monocyclic carbocycle with 3, 4, 5, 6 or 7 ring carbon atoms, wherein that carbocycle may be unsubstituted or substituted with halogen, OH, C_{1-4}-alkyl;

$Hetcyc^X$ is a saturated, partially unsaturated or aromatic, monocyclic heterocycle with 3, 4, 5, 6, 7 ring atoms wherein 1, 2, 3, 4 of said ring atoms is/are a hetero atom(s) selected from N, O and/or S and the remaining are carbon atoms, wherein said heterocycle may be unsubstituted or substituted with R^{X1}, R^{X2}, R^{X3}, R^{X4}, R^{X5}, R^{X6}, R^{X7} and/or R^{X8} which may be the same or different, and wherein that heterocycle is optionally a carboxylic acid bioisostere;

$Hetcyc^Y$ is a saturated, partially unsaturated or aromatic, monocyclic heterocycle with 3, 4, 5, 6, 7 ring atoms wherein 1, 2, 3, 4 of said ring atoms is/are a hetero atom(s) selected from N, O and/or S and the remaining are carbon atoms;

$Hetcyc^{Y1}$ is a saturated or partially unsaturated monocyclic heterocycle with 5 or 6 ring atoms wherein 1 or 2 of said ring atoms are heteroatoms selected from N, O, and/or S and the remaining are carbon atoms;

R^{C1}, R^{C2}, R^{C3}, R^{C4}, R^{C5}, R^{C6} represent independently from each other un-substituted or substituted C_{1-6}-aliphatic;

R^{D1}, R^{D2}, R^{D3}, R^{D4}, R^{D5} represent independently from each other un-substituted or substituted C_{1-6}-aliphatic;

R^{D6}, R^{D7}, R^{D8}, R^{D9}, R^{D10} represent independently from each other un-substituted or substituted C_{1-6}-aliphatic, unsubstituted or substituted C_{1-6}-aliphatoxy, halogen, hydroxy; $Hetar^{Y1}$, CH_2-$Hetar^{Y1}$, Cyc^{Y1}, $Hetcyc^{Y1}$, -CH_2-$Hetcyc^{Y1}$; and/or two of R^{D6}, R^{D7}, R^{D8}, R^{D9}, R^{D10} which are attached to the same ring atom of said carbocycle or heterocycle may form a divalent C_{2-6}-alkylene radical, wherein one or two non-adjacent carbon units of said alkylene radical may optionally be replaced by independently from each other O, N-H, or N-C_{1-4}-alkyl, and wherein that alkylene radical may optionally be substituted with OH, C_{1-4}-alkyl or -O-C_{1-4}-alkyl; and/or two of R^{D6}, R^{D7}, R^{D8}, R^{D9}, R^{D10} which are attached to different ring atoms of said carbocycle or heterocycle may form a divalent C_{1-6}-alkylene radical, wherein one or two non-adjacent carbon units of said alkylene radical may optionally be replaced by independently from each other O, N-H, or N-C_{1-4}-alkyl;

R^{X1}, R^{X2}, R^{X3}, R^{X4}, R^{X5}, R^{X6}, R^{X7}, R^{X8} represent independently from each other un-substituted or substituted C_{1-6}-aliphatic, C_{1-6}-aliphatoxy, -OH, -NR^{2d}-$S(=O)_2$-R^{2g}, $Hetcyc^{Y}$, O-$Hetcyc^{Y}$; and/or

two of R^{X1}, R^{X2}, R^{X3}, R^{X4}, R^{X5}, R^{X6}, R^{X7}, R^{X8} which are attached to the same carbon atom of said heterocycle form a divalent oxo (=O) group; and/or two of R^{X1}, R^{X2}, R^{X3}, R^{X4}, R^{X5}, R^{X6}, R^{X7}, R^{X8} or four of R^{X1}, R^{X2}, R^{X3}, R^{X4}, R^{X5}, R^{X6}, R^{X7}, R^{X8} which are attached to the same sulfur atom of said heterocycle form a divalent oxo (=O) group thereby forming either an -S(=O)- or an -$S(=O)_2$- moiety;

halogen is F, Cl, Br, I;

w is 1 or 2;

x is 0, 1 or 2;

y is 1 or 2;

z is 0, 1 or 2;

or any N-oxide, solvate, tautomer or stereoisomer thereof and/or any pharmaceutically acceptable salt of each of the foregoing, including mixtures thereof in all ratios.

2. Compound according to claim 1, or any N-oxide, solvate, tautomer or stereoisomer thereof and/or any pharmaceutically acceptable salt of each of the foregoing, including mixtures thereof in all ratios, wherein

Z^1 is CH;

Z^2 is CR^{Z2};

Z^3 is CH or N;

R^{Z2} is H; or forms together with R^2 a divalent radical $-S(=O)_2-N(H)-C(=O)-$.

3. Compound according to any of the preceding claims, or any N-oxide, solvate, tautomer or stereoisomer thereof and/or any pharmaceutically acceptable salt of each of the foregoing, including mixtures thereof in all ratios, wherein

at least one of R^{W1}, R^{W2}, R^{W3} and R^{W4} is not H at the same time.

4. Compound according to any of the preceding claims, or any N-oxide, solvate, tautomer or stereoisomer thereof and/or any pharmaceutically acceptable salt of each of the foregoing, including mixtures thereof in all ratios, wherein

(a)

W^1 represents $C-R^{W1}$;

W^2 represents $C-R^{W2}$;

W^3 represents $C-R^{W3}$;

W^4 represents $C-R^{W4}$;

R^{W1} represents H;

R^{W2} represents H;

R^{W3} represents C_{1-6}-aliphatic, -O-C_{1-6}-aliphatic, halogen, -CN, -CH_2-Ar^W or -CH_2-CH_2-Ar^W;

R^{W4} represents H;

Ar^W represents phenyl which may be unsubstituted or mono-substituted with R^{W11};

R^{W11} represents halogen; preferably F;

or

(b)

W^1 represents C-R^{W1};

W^2 represents C-R^{W2};

W^3 represents C-R^{W3};

W^4 represents C-R^{W4};

R^{W1} represents H;

R^{W2} represents C_{1-6}-aliphatic;

R^{W3} represents H,

R^{W4} represents H;

or

(c)

W^1 represents C-R^{W1};

W^2 represents C-R^{W2};

W^3 represents C-R^{W3};

W^4 represents C-R^{W4};

R^{W1} represents H;

R^{W2} represents H;

R^{W3} represents H,

R^{W4} represents C_{1-6}-aliphatic;

or

(d)

W^1 represents C-R^{W1};

W^2 represents N;

W^3 represents C-R^{W3};

W^4 represents C-R^{W4};

R^{W1} represents H;

R^{W3} represents represents C_{1-6}-aliphatic, -O-C_{1-6}-aliphatic, halogen, -CN, -CH_2-Ar^W or -CH_2-CH_2-Ar^W;

R^{W4} represents H;

Ar^W represents phenyl which may be unsubstituted or mono-substituted with R^{W11};

R^{W11} represents halogen; preferably F;

or

(e)

W^1 represents C-R^{W1};

W^2 represents N;

W^3 represents C-R^{W3};

W^4 represents C-R^{W4};

R^{W1} represents H;

R^{W3} represents represents H;

R^{W4} represents C_{1-6}-aliphatic;

or

(f)

W^1 represents C-R^{W1};

W^2 represents C-R^{W2};

W^3 represents N;

W^4 represents C-R^{W4};

R^{W1} represents H;

R^{W2} represents represents C_{1-6}-aliphatic;

R^{W4} represents H;

or

(g)

W^1 represents C-R^{W1};

W^2 represents C-R^{W2};

W^3 represents N;

W^4 represents C-R^{W4};

R^{W1} represents H;

R^{W2} represents represents H;

R^{W4} represents C_{1-6}-aliphatic;

or

(h)

W^1 represents C-R^{W1};

W^2 represents C-R^{W2};

W^3 represents C-R^{W3};

W^4 represents N;

R^{W1} represents H;

R^{W2} represents H;

R^{W3} represents represents C_{1-6}-aliphatic, -O-C_{1-6}-aliphatic, halogen, -CN, -CH_2-Ar^W or -CH_2-CH_2-Ar^W;

Ar^W represents phenyl which may be unsubstituted or mono-substituted with R^{W11};

R^{W11} represents halogen; preferably F;

or

(i)

W^1 represents C-R^{W1};

W^2 represents C-R^{W2};

W^3 represents C-R^{W3};

W^4 represents C-R^{W4};

R^{W1} represents H;

R^{W2} represents C_{1-6}-aliphatic;

R^{W3} represents C_{1-6}-aliphatic;

R^{W4} represents H.

5. Compound according to any of the preceding claims, or any N-oxide, solvate, tautomer or stereoisomer thereof and/or any pharmaceutically acceptable salt of each of the foregoing, including mixtures thereof in all ratios, wherein

(a)

W^1 represents CH;

W^2 represents CH;

W^3 represents C-R^{W3};

W^4 represents CH;

R^{W3} represents methyl, ethyl, 2-propyl, trifluoromethyl, methoxy, trifluoromethoxy, F, -CN, -CH_2-phenyl, -CH_2-(2-fluorophenyl), -CH_2-(3-fluorophenyl), -CH_2-(4-fluorophenyl);

or

(d)

W^1 represents CH;

W^2 represents N;

W^3 represents C-R^{W3};

W^4 represents CH;

R^{W3} represents methyl, 2-propyl, trifluoromethyl, methoxy, trifluoromethoxy, F, -CN, -CH_2-phenyl, -CH_2-(2-fluorophenyl), -CH_2-(3-fluorophenyl), -CH_2-(4-fluorophenyl);

or

(h)

W^1 represents CH;

W^2 represents CH;

W^3 represents C-R^{W3};

W^4 represents N;

R^{W3} represents methyl, 2-propyl, trifluoromethyl, methoxy, trifluoromethoxy, F, -CN, -CH_2-phenyl, -CH_2-(2-fluorophenyl), -CH_2-(3-fluorophenyl), -CH_2-(4-fluorophenyl).

6. Compound according to any of the preceding claims, or any N-oxide, solvate, tautomer or stereoisomer thereof and/or any pharmaceutically acceptable salt of each of the foregoing, including mixtures thereof in all ratios, wherein

R^1 represents Ar^1, $Hetar^1$, Cyc^1, $Hetcyc^1$, L^1-Ar^1, L^1-$Hetar^1$, L^2-Cyc^1, L^2-$Hetcyc^1$, straight-chain or branched C_{1-6}-alkyl which is substituted with 1, 2 or 3 F;

Ar^1 is a mono- or bicyclic aryl with 6 or 10 ring carbon atoms, wherein that aryl may be unsubstituted or substituted with substituents R^{B1}, R^{B2} and/or R^{B3} which may be the same or different; preferably phenyl or naphthalenyl, in particular phenyl, which may be unsubstituted or substituted with substituents R^{B1} and or R^{B2} which may be the same or different;

$Hetar^1$ is a monocyclic heteroaryl with 5 or 6 ring atoms or a bicyclic heteroaryl with 9 or 10 ring atoms wherein 1, 2 or 3 of said ring atoms is/are a hetero atom(s) selected from N, O and/or S and the remaining are carbon atoms, wherein that heteroaryl may be unsubstituted or substituted with substituents R^{B1}, R^{B2} and/or R^{B3} which may be the same or different; preferably the heteroaryl is unsubstituted or substituted with substituents R^{B1} and/or R^{B2} which may be the same or different;

Cyc^1 is a saturated or partially unsaturated, mono- or bicyclic carbocycle with 3, 4, 5, 6, 7 or 8 ring carbon atoms, wherein that carbocycle may be unsubstituted or substituted with R^{B8} and/or R^{B9} which may be the same or different; and wherein that carbocycle may optionally be fused to Ar^X via 2 adjacent ring atoms of said Ar^X and wherein that fused carbocycle may be unsubstituted or substituted with R^{C1} and/or R^{C2} which may be the same or different;

$Hetcyc^1$ is a saturated or partially unsaturated, monocyclic heterocycle with 5 or 6 ring atoms wherein 1 or 2 of said ring atoms is/are a hetero atom(s) selected from N, O and/or S and the remaining are carbon atoms, wherein that heterocycle may be unsubstituted or substituted with R^{B8} and/or R^{B9} which may be the same or different, wherein, if one of the heteroatoms is S, then that heterocycle may also be substituted with R^{B8}, R^{B9}, R^{B10} and R^{B11}; preferably a saturated monocyclic heterocycle with 5 or 6 ring atoms wherein 1 of said ring atoms is a hetero atom selected from O and S and the remaining are carbon atoms, wherein that heterocycle may be unsubstituted or substituted with R^{B8} and/or R^{B9} which may be the same or different, wherein, if one of the heteroatoms is

S, then that heterocycle may also be substituted with R^{B8}, R^{B9}, R^{B10} and R^{B11};

L^1 is a divalent radical selected from the group consisting of -S(=O)$_2$-, un-substituted or substituted, straight-chain or branched C_{1-6}-alkylene or C_{2-6}-alkenylene, in both of which one of the carbon units of the alkylene or alkenylene chain may be replaced by -O-; preferably selected from the group consisting of -S(=O)$_2$-, -CH$_2$-, -CH$_2$-CH$_2$-, -CH$_2$-CH$_2$-C(CH$_3$)H-, -CH$_2$-CH$_2$-C(CH$_3$)$_2$-, -CH$_2$-CH$_2$-O-CH$_2$-, -CH$_2$-CH=CH-;

L^2 is a divalent radical selected from the group consisting of un-substituted or substituted, straight-chain or branched C_{1-6}-alkylene or C_{2-6}-alkenylene, in both of which one of the carbon units of the alkylene or alkenylene chain may be replaced by -O-; preferably selected from the group consisting of -CH$_2$-, -CH$_2$-CH$_2$-;

R^{B1}, R^{B2}, R^{B3} represent independently from each other straight-chain or branched C_{1-6}-alkyl, which C_{1-6}-alkyl may be unsubstituted or monosubstituted with -CN or substituted with 1, 2 or 3 halogen, straight-chain or branched C_{1-4}-alkoxy, which C_{1-4}-alkoxy may be unsubstituted or substituted with 1, 2 or 3 halogen, -O-CH$_2$-C≡CH, straight-chain or branched -S-C_{1-4}-alkyl, which -S-C_{1-4}-alkyl may be unsubstituted or substituted with 1, 2 or 3 halogen, F, Cl, Br, -CN, -S(=O)-C_{1-3}-alkyl, S(=O)$_2$-C_{1-3}-alkyl, -N(C_{1-3}-alkyl)$_2$, Ar^2, -CH$_2$-Ar^2, $Hetar^2$, Cyc^2, $Hetcyc^2$;
or two adjacent R^{B1}, R^{B2} and/or R^{B3} form together a divalent -C_{3-4}-alkylene radical in which one of the alkylene carbon units may be replaced by a carbonyl unit (-C(=O)-), or a divalent -O-C_{2-3}-alkylene radical;

Ar^2 is phenyl;

$Hetar^2$ is a monocyclic heteroaryl with 5 or 6 ring atoms wherein 1, 2, 3, 4, 5 of said ring atoms is/are a hetero atom(s) selected from N, O and/or S and the remaining are carbon atoms; preferably a monocyclic heteroaryl with 5 ring atoms wherein 1 of said ring atoms is N and the remaining are carbon atoms or 1 of said ring atoms is N and 1 of said ring atoms is S and the remaining are carbon atoms;

Cyc^2 is cyclopropyl, cyclobutyl, cyclopentyl, each of which may be unsubstituted or mono-substituted with R^{D6} or di-substituted with independently from each other R^{D6} and R^{D7};

$Hetcyc^2$ is pyrrolidinyl, piperidinyl, each of which may unsubstituted or mono-substituted with R^{D6} or di-substituted with independently from each other R^{D6} and R^{D7};

R^{B8}, R^{B9} represent independently from each other F, C_{1-2}-alkyl, which C_{1-2}-alkyl may be unsubstituted or substituted with 1, 2 or 3 F, C_{1-2}-alkoxy, Ar^Y; or

R^{B8} and R^{B9} are attached to the same carbon atom of said carbocycle Cyc^1 or said heterocycle $Hetcyc^1$ and form a divalent oxo (=O) group; or

R^{B8} and R^{B9} and R^{B10} and R^{B11} are attached to the same sulfur atom of said heterocycle and form two divalent oxo (=O) groups thereby forming an $-S(=O)_2-$ moiety;

Ar^X is an unsubstituted benzo ring;

Ar^Y is phenyl;

R^{C1}, R^{C2} represent independently from each other straight-chain or branched C_{1-4}-alkyl, which may be independently from each other be substituted with 1, 2, or 3 F atoms;

R^{D6}, $R^{D7,}$ represent independently from each other C_{1-6}-alkyl which may be substituted with 1, 2, or 3 F atoms or 1 hydroxy group; or hydroxy;

halogen is F, Cl, Br.

7. Compound according to any of the preceding claims, or any N-oxide, solvate, tautomer or stereoisomer thereof and/or any pharmaceutically acceptable salt of each of the foregoing, including mixtures thereof in all ratios, wherein

R^2 represents $-C(=O)-OR^{2a}$ or $Hetcyc^X$; preferably $-C(=O)-OR^{2a}$;

R^{2a} represents H, straight-chain or branched, unsubstituted or substituted C_{1-4}-alkyl or Cat; preferably H, methyl, ethyl or Cat;

Cat represents a monovalent cation selected from the group consisting of lithium (Li), sodium (Na) and potassium (K); preferably sodium;

$Hetcyc^X$ represents 1H-1,2,3,4-tetrazol-5-yl, 2H-1,2,3,4-tetrazol-5-yl, 2-methyl-2H-1,2,3,4-tetrazol-5-yl, 5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl (2H-1,2,4-oxadiazol-5-on-3-yl), 5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl (4H-1,2,4-oxadiazol-5-on-3-yl), 3-bromo-4,5-dihydro-1,2-oxazol-5-yl, 3-chloro-4,5-dihydro-1,2-oxazol-5-yl, 3-(1H-1,2,3-triazol-1-yl)-4,5-dihydro-1,2-oxazol-5-yl, 3-(2H-1,2,3-triazol-2-yl)-4,5-dihydro-1,2-oxazol-5-yl, 3-(pyrimidin-5-yloxy)-4,5-dihydro-1,2-oxazol-5-yl, 3-hydroxy-oxetan-3-yl, 5-hydroxy-4H-pyran-4-on-2-yl, 3,3-difluoropyrrolidin-2-on-4-yl, 3,3-difluoropyrrolidin-2-on-5-yl, 3,3-difluoro-2,3-dihydro-1H-pyrrol-2-on-4-yl, 3,3-difluoro-2,3-dihydro-1H-pyrrol-2-on-5-yl.

8. Compound according to any of claims 1 to 6, or any N-oxide, solvate, tautomer or stereoisomer thereof and/or any pharmaceutically acceptable salt of each of the foregoing, including mixtures thereof in all ratios, wherein

R^2 represents $-C(=O)-NR^{2b}R^{2c}$; and wherein

(a)

R^{2b} represents hydrogen,

R^{2c} represents hydrogen; straight-chain or branched C_{1-8}-alkyl which may be unsubstituted or substituted with R^{E1}, R^{E2}, R^{E3}, R^{E4} and/or R^{E5} which may be the same or different; Cyc^2 or $Hetcyc^2$, wherein

R^{E1}, R^{E2}, R^{E3}, R^{E4} and/or R^{E5} represent independently from each other halogen, in particular F; $-NR^{Ea}R^{Eb}$, -OH, OR^{Ec}, Ar^E, $Hetar^E$, Cyc^E, $Hetcyc^E$;

Ar^E is a mono- or bicyclic aryl with 6 or 10 ring carbon atoms, wherein that aryl may be unsubstituted or substituted with substituents R^{F1}, R^{F2} and/or R^{F3} which may be the same or different; preferably phenyl or naphthalenyl, in particular phenyl;

$Hetar^E$ is a monocyclic heteroaryl with 5 or 6 ring atoms or a bicyclic heteroaryl with 9 or 10 ring atoms wherein 1, 2, 3, or 4 of said ring atoms is/are a hetero atom(s) selected from N, O and/or S and the remaining are carbon atoms, wherein that heteroaryl may be unsubstituted or substituted with substituents R^{F1}, R^{F2} and/or R^{F3} which may be the same or different; in particular the heteroaryl is a moncyclic heteroaryl with 5 or

6 ring atoms which may be unsubstituted or substituted with substituents R^{F1} and/or R^{F2} which may be the same or different; preferably the heteroaryl is selected from the group consisting of imidazolyl, 1H-imidazol-1-yl, 1H-imidazol-2-yl, each of which unsubstituted or monosubstituted with C_{1-4}-alkyl; pyridyl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, each of which may be unsubstituted or monosubstituted with -F; pyrimidinyl, pyrimidin-2-yl, pyrimidin-3-yl, pyrimidin-4-yl, pyrimidin-5-yl; pyrazinyl, pyrazin-2-yl pyridazinyl, pyridazin-3-yl; furanyl, pyrrolyl, pyrazolyl, oxazolyl, isoxazolyl; oxadiazolyl, triazolyl, thiazolyl, isothiazolyl;

Cyc^E is a saturated or partially unsaturated, mono- or bicyclic carbocycle with 3, 4, 5, 6, 7 or 8 ring carbon atoms, wherein that carbocycle may be unsubstituted or substituted with R^{G1} and/or R^{G2} which may be the same or different: in particular, a saturated monocyclic carbocycle with 3, 4, 5, or 6 ring carbon atoms, wherein that carbocycle may be unsubstituted or substituted with R^{G1} and/or R^{G2} which may be the same or different; preferably cyclopropyl, cyclobutyl, cyclohexenyl;

$Hetcyc^E$ is a saturated or partially unsaturated, monocyclic heterocycle with 4, 5 or 6 ring atoms wherein 1 or 2 of said ring atoms is/are a hetero atom(s) selected from N, O and/or S and the remaining are carbon atoms, wherein that heterocycle may be unsubstituted or substituted with R^{G1} and/or R^{G2} which may be the same or different; in particular a saturated monocyclic heterocycle with 5 or 6 ring atoms wherein 1 or 2 of said ring atoms is/are a hetero atom(s) selected from N and/or O and the remaining are carbon atoms, wherein that heterocycle may be unsubstituted or monosubstituted with R^{G1}; preferably tetrahydrofuranyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl each of which may be unsubstituted or monosubstituted with -OH; pyrrolindinyl, pyrrolindin-1-yl, pyrrolindin-2-yl, pyrrolindin-3-yl, each of which may be unsubstituted or monosubstituted with -OH; piperidinyl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, each of which may be unsubstituted or monosubstituted with -OH; morpholinyl, morpholin-1-yl, morpholin-2-yl,

each of which may be unsubstituted or mono-substituted with methyl; 1,4-dioxanyl; dihydropyranyl, tetrahydropyranyl, tetrahydropyran-3-yl;

R^{Ea}, R^{Eb} represent independently from each other H, C_{1-4}-alkyl, -C(=O)-OC_{1-4}-alkyl; in particular both represent H or one represents H and the other represents C(=O)-O-tert.-butyl;

R^{Ec} represents H or C_{1-4}-alkyl, in particular H or methyl;

R^{F1}, R^{F2} and/or R^{F3} represent independently from each other straight-chain or branched C_{1-6}-alkyl, which C_{1-6}-alkyl may be unsubstituted or monosubstituted with -CN, OH, -O-C_{1-4}-alkyl or substituted with 1, 2 or 3 halogen, straight-chain or branched C_{1-4}-alkoxy, which C_{1-4}-alkoxy may be unsubstituted or substituted with 1, 2 or 3 halogen, straight-chain or branched -S-C_{1-4}-alkyl, which -S-C_{1-4}-alkyl may be unsubstituted or substituted with 1, 2 or 3 halogen, F, Cl, Br, -CN, -S(=O)-C_{1-3}-alkyl, $S(=O)_2$-C_{1-3}-alkyl, -NH_2, -NH(C_{1-3}-alkyl), -N(C_{1-3}-alkyl)$_2$, -OH; in particular methyl, hydroxymethyl, methoxymethyl, F, cyclopropyl, cyclobutyl; preferably only one of R^{F1}, R^{F2} and R^{F3} is present and represents methyl or F;

and/or two of R^{F1}, R^{F2}, R^{F3} which are attached to two different ring atoms of that aryl or heteroaryl form a divalent C_{1-6}-alkylene radical wherein optionally one or two non-adjacent carbon units of that alkylene radical may be replaced by independently from each other O, NH, N-C_{1-4}-alkyl, in particular –$(CH_2)_4$-, -CH_2-O-$(CH_2)_2$-;

R^{G1} and/or R^{G2} represent independently from each other halogen, hydroxy, unsubstituted or substituted C_{1-6}-aliphatic, in particular C_{1-4}-alkyl optionally substituted with OH, C_{1-6}-aliphatoxy, in particular -O-C_{1-4}-alkyl, -C(=O)-O-C_{1-4}-alkyl, $Hetar^{Y2}$, -CH_2-$Hetar^{Y2}$, $Hetcyc^{Y2}$, in particular hydroxy; preferably only one of R^{G1} and R^{G2} is present and represents hydroxy;

and/or R^{G1} and R^{G2} which are attached to the same ring atom of that carbocycle or heterocycle form a divalent C_{2-6}-alkylene radical wherein optionally one or two non-adjacent carbon units of that alkylene radical may be replaced by independently from each other O, NH, N-C_{1-4}-alkyl,

and wherein that alkylene radical may optionally be substituted with OH, C_{1-4}-alkyl or -O-C_{1-4}-alkyl, in particular $–(CH_2)_2$-O-CH_2-, $–(CH_2)_2$-O-$(CH_2)_2$-;

and/or R^{G1} and R^{G2} which are attached to two different ring atoms of that carbocycle or heterocycle form a divalent C_{1-6}-alkylene radical wherein optionally one or two non-adjacent carbon units of that alkylene radical may be replaced by independently from each other O, NH, N-C_{1-4}-alkyl, in particular -CH_2-;

Cyc^2 is a saturated monocyclic carbocycle with 3, 4, 5, 6 or 7 ring carbon atoms, wherein that carbocycle may be unsubstituted or substituted independently from each other with R^{D6}, R^{D7}, R^{D8}, R^{D9} and/or R^{D10} wherein that carbocycle may optionally be fused to Ar^Z or $Hetar^Z$ via 2 adjacent ring atoms and wherein that fused carbocycle may optionally further be substituted with independently from each other R^{C1}, R^{C2} and/or R^{C3};

$Hetcyc^2$ is a saturated monocyclic heterocycle with 4, 5 or 6 ring atoms wherein 1 or 2 of said ring atoms is/are a hetero atom(s) selected from N, O and/or S and the remaining are carbon atoms, wherein that heterocycle may be unsubstituted or substituted independently from each other with R^{D6}, R^{D7}, R^{D8}, R^{D9} and/or R^{D10} wherein that heterocycle may optionally be fused to Ar^Z or $Hetar^Z$ and wherein that fused heterocycle may optionally further be substituted with independently from each other R^{C1}, R^{C2} and/or R^{C3};

R^{C1}, R^{C2}, R^{C3} represent independently from each other C_{1-4}-alkyl;

R^{D6}, R^{D7}, R^{D8}, R^{D9}, R^{D10} represent independently from each other halogen, in particular F; hydroxy; C_{1-4}-alkyl optionally substituted with -OH and/or halogen, in particular methyl, hydroxymethyl, 2-fluorethyl; -O-C_{1-4}-alkyl, in particular methoxy, ethoxy; $Hetar^{Y1}$, -CH_2-$Hetar^{Y1}$, Cyc^{Y1}, $Hetcyc^{Y1}$, -CH_2-$Hetcyc^{Y1}$;

and/or two of R^{D6}, R^{D7}, R^{D8}, R^{D9}, R^{D10} which are attached to the same ring atom of that carbocycle or heterocycle form a divalent C_{2-6}-alkylene radical wherein optionally one or two non-adjacent carbon units of that

alkylene radical may be replaced by independently from each other O, NH, N-C_{1-4}-alkyl, and wherein that alkylene radical may optionally be substituted with OH, C_{1-4}-alkyl or -O-C_{1-4}-alkyl, in particular $–(CH_2)_3$-, $–CH_2$-$CH(OC_2H_5)$-CH_2-, $–(CH_2)_2$-O-$(CH_2)_2$-;

and/or two of R^{D6}, R^{D7}, R^{D8}, R^{D9}, R^{D10} which are attached to two different ring atoms of that carbocycle or heterocycle form a divalent C_{1-6}-alkylene radical wherein optionally one or two non-adjacent carbon units of that alkylene radical may be replaced by independently from each other O, NH, N-C_{1-4}-alkyl, in particular -CH_2-, $–(CH_2)_3$-, -O-$(CH_2)_2$-, -O-$(CH_2)_3$-;

Ar^Z is benzo;

$Hetar^{Y1}$ is a 5 or 6 membered monocyclic heteroaryl wherein 1, 2, 3, 4 ring atoms are hetero atoms selected from N, O and/or S and the remaining are carbon atoms, wherein that heteroaryl may be unsubstituted or substituted with F, C_{1-4}-alkyl which may optionally be substituted with OH; in particular pyrrolyl, thiophenyl, pyrazolyl, methylpyrazolyl, imidazolyl, methylimidazolyl, triazolyl, oxadiazolyl, methyloxadiazolyl, pyrdinyl, fluoropyrdinyl, methylpyridinyl, pyrimidinyl, methylpyrimidinyl;

$Hetar^{Y2}$ is a 5 or 6 membered monocyclic heteroaryl wherein 1, 2, 3, 4 ring atoms are hetero atoms selected from N, O and/or S and the remaining are carbon atoms, wherein that heteroaryl may be unsubstituted or substituted with halogen, C_{1-4}-alkyl which may optionally be substituted with OH; in particular pyrrolyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, hydroxymethyloxazolyl;

$Hetar^Z$ is pyrrole, N-methyl-pyrrole, pyrazole, imidazole, triazole;

Cyc^{Y1} is a saturated monocyclic carbocycle with 3, 4, 5, 6 or 7 ring carbon atoms, wherein that carbocycle may be unsubstituted or substituted with halogen, OH, C_{1-4}-alkyl, in particular cyclopropyl;

$Hetcyc^{Y1}$ is a saturated or partially unsaturated monocyclic heterocycle with 5 or 6 ring atoms wherein 1 or 2 of said ring atoms are heteroatoms selected from N, O, and/or S and the remaining are carbon atoms; in particular tetrahydrofuranyl;

$Hetcyc^{Y2}$ is a saturated or partially unsaturated monocyclic heterocycle with 5 or 6 ring atoms wherein 1 or 2 of said ring atoms are heteroatoms selected from N, O, and/or S and the remaining are carbon atoms; in particular tetrahydrofuranyl, morpholinyl, tetrahydropyranyl;

or

(b)

R^{2b} and R^{2c} form together with the nitrogen atom to which they are attached to a saturated or partially unsaturated heterocycle with 3, 4, 5, 6, 7 ring atoms wherein 1 of said ring atoms is said nitrogen atom and no or one further ring atom is a hetero atom selected from N, O or S and the remaining are carbon atoms which heterocycle is optionally substituted with independently from each other R^{Y1}, R^{Y2}, R^{Y3}, R^{Y4} and/or R^{Y5}; wherein that heterocycle may optionally be fused with $Hetar^{Z}$; and wherein that heterocycle is preferably selected from the group consisting of: azetidine, pyrrolidine, piperidine, piperazine, morpholine

R^{Y1}, R^{Y2}, R^{Y3}, R^{Y4}, R^{Y5} represent independently from each other halogen, in particular F; $-NH_2$, $-N(H)-C_{1-4}$-alkyl, $-N(H)-C(=O)-O-C_{1-4}$-alkyl, $-N(C_{1-4}\text{-alkyl})_2$; -OH; C_{1-4}-alkyl optionally substituted with -OH, $-O-C_{1-4}$-alkyl, $-O-C_{3-7}$-cycloalkyl, $-O-CH_2-C_{3-7}$-cycloalkyl, in particular methyl, $-CH_2OH$, $-(CH_2)_2OH$, $-(CH_2)_3OH$, $-CH_2OCH_3$, $-(CH_2)_2OCH_3$, cyclopropylmethoxy; $-O-C_{1-4}$-alkyl, in particular methoxy; $Hetar^{Y2}$; $-CH_2-Hetar^{Y2}$; $Hetcyc^{Y2}$;

and/or two of R^{Y1}, R^{Y2}, R^{Y3}, R^{Y4}, R^{Y5} which are attached to the same ring atom of that heterocycle form a divalent C_{2-6}-alkylene radical wherein optionally one or two non-adjacent carbon units of that alkylene radical may be replaced by independently from each other O, NH, $N-C_{1-4}$-alkyl, in particular $-(CH_2)_4-$, $-(CH_2)_2-O-(CH_2)_2-$, $-(CH_2)_2-O-(CH_2)_3-$;

and/or two of R^{Y1}, R^{Y2}, R^{Y3}, R^{Y4}, R^{Y5} which are attached to two different ring atoms of that heterocycle form a divalent C_{1-6}-alkylene radical wherein optionally one or two non-adjacent carbon units of that alkylene radical may be replaced by independently from each other O, NH, $N-C_{1-4}$-alkyl, in particular $-(CH_2)_4-$;

$Hetar^{Y2}$ is a 5 or 6 membered monocyclic heteroaryl wherein 1, 2, 3, 4 ring atoms are hetero atoms selected from N, O and/or S and the remaining are carbon atoms, wherein that heteroaryl may be unsubstituted or substituted with halogen, C_{1-4}-alkyl which may optionally be substituted with OH; in particular pyrrolyl, thiophenyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, hydroxymethyloxazolyl, pyrimidinyl;

$Hetar^{Z}$ is pyrrole, N-methyl-pyrrole, pyrazole, imidazole, triazole;

$Hetcyc^{Y2}$ is a saturated or partially unsaturated monocyclic heterocycle with 5 or 6 ring atoms wherein 1 or 2 of said ring atoms are heteroatoms selected from N, O, and/or S and the remaining are carbon atoms; in particular tetrahydrofuranyl, morpholinyl, tetrahydropyranyl;

or

(c)

R^{2b} represents a straight-chain of branched C_{1-4}-alkyl optionally substituted with OH; in particular methyl, 2-hydroxyethyl;

and

R^{2c} represents Cyc^2, $Hetcyc^2$ or straight-chain or branched C_{1-8}-alkyl which may be unsubstituted or substituted with independently from each other R^{E1}, R^{E2}, R^{E3}, R^{E4} and/or R^{E5} which may be the same or different; and wherein Cyc^2, $Hetcyc^2$, R^{E1}, R^{E2}, R^{E3}, R^{E4} and R^{E5} are as defined above under (a).

9. Compound according to any of claims 1 to 6 or 8, or any N-oxide, solvate, tautomer or stereoisomer thereof and/or any pharmaceutically acceptable salt of each of the foregoing, including mixtures thereof in all ratios, wherein

R^2 represents $-C(=O)-NR^{2b}R^{2c}$; and wherein

(a)

R^{2b} represents hydrogen,

R^{2c} represents hydrogen; straight-chain or branched C_{1-8}-alkyl which may be unsubstituted or substituted with R^{E1}, R^{E2}, R^{E3}, R^{E4} and/or R^{E5} which may be the same or different; Cyc^2 or $Hetcyc^2$, wherein

R^{E1}, R^{E2}, R^{E3}, R^{E4} and/or R^{E5} represent independently from each other halogen, in particular F; -$NR^{Ea}R^{Eb}$, -OH, OR^{Ec}, Ar^E, $Hetar^E$, Cyc^E, $Hetcyc^E$;

Ar^E is a mono- or bicyclic aryl with 6 or 10 ring carbon atoms, wherein that aryl may be unsubstituted or substituted with substituents R^{F1}, R^{F2} and/or R^{F3} which may be the same or different; preferably phenyl or naphthalenyl, in particular phenyl;

$Hetar^E$ is a monocyclic heteroaryl with 5 or 6 ring atoms or a bicyclic heteroaryl with 9 or 10 ring atoms wherein 1, 2, 3, or 4 of said ring atoms is/are a hetero atom(s) selected from N, O and/or S and the remaining are carbon atoms, wherein that heteroaryl may be unsubstituted or substituted with substituents R^{F1}, R^{F2} and/or R^{F3} which may be the same or different; in particular the heteroaryl is a moncyclic heteroaryl with 5 or 6 ring atoms which may be unsubstituted or substituted with substituents R^{F1} and/or R^{F2} which may be the same or different; preferably the heteroaryl is selected from the group consisting of imidazolyl, 1H-imidazol-1-yl, 1H-imidazol-2-yl, each of which unsubstituted or monosubstituted with C_{1-4}-alkyl; pyridyl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, each of which may be unsubstituted or monosubstituted with -F; pyrimidinyl, pyrimidin-2-yl, pyrimidin-3-yl, pyrimidin-4-yl;

Cyc^E is a saturated or partially unsaturated, mono- or bicyclic carbocycle with 3, 4, 5, 6, 7 or 8 ring carbon atoms, wherein that carbocycle may be unsubstituted or substituted with R^{G1} and/or R^{G2} which may be the same or different: in particular, a saturated monocyclic carbocycle with 3, 4, 5, or 6 ring carbon atoms, wherein that carbocycle may be unsubstituted or substituted with R^{G1} and/or R^{G2} which may be the same or different; preferably cyclobutyl;

$Hetcyc^E$ is a saturated or partially unsaturated, monocyclic heterocycle with 5 or 6 ring atoms wherein 1 or 2 of said ring atoms is/are a hetero atom(s) selected from N, O and/or S and the remaining are carbon atoms, wherein that heterocycle may be unsubstituted or substituted with R^{G1} and/or R^{G2} which may be the same or different; in particular a saturated monocyclic heterocycle with 5 or 6 ring atoms wherein 1 or 2 of said ring

atoms is/are a hetero atom(s) selected from N and/or O and the remaining are carbon atoms, wherein that heterocycle may be unsubstituted or monosubstituted with R^{G1}; preferably tetrahydrofuranyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl each of which may be unsubstituted or monosubstituted with -OH; pyrrolindinyl, pyrrolindin-1-yl, pyrrolindin-2-yl, pyrrolindin-3-yl, each of which may be unsubstituted or monosubstituted with -OH; piperidinyl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, each of which may be unsubstituted or monosubstituted with -OH; morpholinyl, morpholin-1-yl, morpholin-2-yl;

R^{Ea}, R^{Eb} represent independently from each other H, C_{1-4}-alkyl, -C(=O)-OC_{1-4}-alkyl; in particular both represent H or one represents H and the other represents C(=O)-O-tert.-butyl;

R^{Ec} represents H or C_{1-4}-alkyl, in particular H or methyl;

R^{F1}, R^{F2} and/or R^{F3} represent independently from each other straight-chain or branched C_{1-6}-alkyl, which C_{1-6}-alkyl may be unsubstituted or monosubstituted with -CN, or substituted with 1, 2 or 3 halogen, straight-chain or branched C_{1-4}-alkoxy, which C_{1-4}-alkoxy may be unsubstituted or substituted with 1, 2 or 3 halogen, straight-chain or branched -S-C_{1-4}-alkyl, which -S-C_{1-4}-alkyl may be unsubstituted or substituted with 1, 2 or 3 halogen, F, Cl, Br, -CN, -S(=O)-C_{1-3}-alkyl, $-NH_2$, -NH(C_{1-3}-alkyl), -N(C_{1-3}-alkyl)$_2$, -OH; in particular methyl, F; preferably only one of R^{F1}, R^{F2} and R^{F3} is present and represents methyl or F;

R^{G1} and/or R^{G2} represent independently from each other halogen, hydroxy, unsubstituted or substituted C_{1-6}-aliphatic, in particular hydroxy; preferably only one of R^{G1} and R^{G2} is present and represents hydroxy;

Cyc^2 is a saturated monocyclic carbocycle with 3, 4, 5, 6 or 7 ring carbon atoms, wherein that carbocycle may be unsubstituted or mono-substituted with R^{D6}, wherein

R^{D6} is C_{1-4}-alkyl which is unsubstituted or mono-substituted with -OH, in particular -CH_2OH;

in particular Cyc^2 is cyclopropyl, cyclobutyl or 1-hydroxymethyl-cyclobutyl;

Hetcyc^2 is a saturated monocyclic heterocycle with 5 or 6 ring atoms wherein 1 or 2 of said ring atoms is/are a hetero atom(s) selected from N, O and/or S and the remaining are carbon atoms, wherein that heterocycle may be unsubstituted or mono-substituted with hydroxy; in particular tetrahydrofuranyl or hydroxytetrahydrofuranyl; preferably 4-hydroxytetrahydrofuran-3-yl;

or

(b)

R^{2b} and R^{2c} form together with the nitrogen atom to which they are attached to a pyrrolidinyl or piperidinyl ring each of which is unsubstituted or mono-substituted with -OH or di-substituted with independently from each other C_{1-4}-alkyl and/or -OH; preferably form together with the nitrogen atom to which they are attached a 3-hydroxypyrrolidinyl, 2-methyl-3-hydroxypyrrolidinyl or 3-hydroxypiperidinyl ring.

10. Compound according to any of claims 1 to 6, or any N-oxide, solvate, tautomer or stereoisomer thereof and/or any pharmaceutically acceptable salt of each of the foregoing, including mixtures thereof in all ratios, wherein

R^2 represents $-(CH_2)_x-NR^{2d}-C(=O)-R^{2e}$, $-S-R^{2f}$, $-S(=O)-R^{2f}$, $-S(=O)_2-R^{2g}$, $-S(=O)_2-NR^{2h}R^{2i}$, $-S(=O)_2-OH$, $-S(=O)(=NR^{2j})-OH$, $-S(=O)(=NR^{2j})-R^{2g}$, $-S(=O)(=NR^{2k})-NR^{2l}R^{2m}$, $-(CH_2)_z-NR^{2d}-S(=O)_2-R^{2g}$, $-N=S(=O)-R^{2s}R^{2t}$, $-C(=O)-N=S(=O)-R^{2s}R^{2t}$, $-C(=O)-N=S(=N-R^{2u})-R^{2s}R^{2t}$; in particular $-S(=O)-R^{2f}$, $-S(=O)_2-R^{2g}$, $-S(=O)_2-NR^{2h}R^{2i}$, $-S(=O)(=NR^{2j})-R^{2g}$, $-S(=O)(=NR^{2k})-NR^{2l}R^{2m}$, $-(CH_2)_z-NR^{2d}-S(=O)_2-R^{2g}$, $-C(=O)-N=S(=O)-R^{2s}R^{2t}$, $-C(=O)-N=S(=N-R^{2u})-R^{2s}R^{2t}$; preferably, $-S-CH_3$, $-S(=O)-CH_3$, $-S(=O)_2-CH_3$, $-S(=O)_2-NH_2$, $-S(=O)_2-NHCH_3$, $-S(=O)(=NH)-CH_3$, $S(=O)(=NH)-N(CH_3)_2$, $-NH-S(=O)_2-CH_3$, $-N(CH_3)-S(=O)_2-CH_3$, $-NH-S(=O)_2-CH=CH_2$, $-CH_2-NH-S(=O)_2-CH=CH_2$;

R^{2e} represents H, C_{1-6}-alkyl optionally substituted with -OH or a monocyclic 5- or 6-membered heteroaryl; C_{3-7}-cycloalkyl, monocyclic 5- or 6-membered heteroaryl; in particular H, methyl, hydroxymethyl,

methylpyridin-2-yl, methylpyridine-3-yl, methylpyridine-4-yl, cyclopropyl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl;

R^{2f}, R^{2g} represent independently from each other un-substituted or substituted C_{1-8}-aliphatic; in particular independently from each other C_{1-4}-alkyl or C_{2-4}-alkenyl; preferably independently from each other methyl or -$CH{=}CH_2$:

R^{2h}, R^{2i} represent independently from each other H, un-substituted or substituted C_{1-8}-aliphatic, aryl, heterocyclyl, heteroaryl; or form together with the nitrogen atom to which they are attached to an unsubstituted or substituted saturated, partially unsaturated or aromatic heterocycle with 3, 4, 5, 6, 7 ring atoms wherein 1 of said ring atoms is said nitrogen atom and no or one further ring atom is a hetero atom selected from N, O or S and the remaining are carbon atoms; in particular independently from each other H or C_{1-4}-alkyl optionally substituted with -OH, pyridyl, pyrimidyl, pyrazinyl or pyridazinyl or form together with the nitrogen atom to which they are attached to a pyrrolidinyl ring which ring is optionally substituted with -OH and/or phenyl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-5-yl;

R^{2d}, R^{2j}, R^{2k}represent independently from each other H, un-substituted or substituted C_{1-8}-aliphatic; in particular H, methyl;

R^{2l}, R^{2m} represent independently from each other H, un-substituted or substituted C_{1-8}-aliphatic; or form together with the nitrogen atom to which they are attached to an unsubstituted or substituted saturated, partially unsaturated or aromatic heterocycle with 3, 4, 5, 6, 7 ring atoms wherein 1 of said ring atoms is said nitrogen atom and no or one further ring atom is a hetero atom selected from N, O or S and the remaining are carbon atoms; in particular C_{1-4}-alkyl; preferably methyl;

R^{2s}, R^{2t} represent independently from each other C_{1-6}-alkyl which may optionally be substituted with -OH, O-C_{1-4}-alkyl, NH_2, NHC_{1-4}-alkyl, N(C_{1-4}-alkyl)$_2$, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl; in particular methyl, ethyl, 2-hydroxyethyl, 3-hydroxy propyl, 2-aminoethyl, 3-(N,N-dimethylamino)propyl; or form together a divalent C_{3-4}-alkylene radical

which may optionally be substituted with $-NH_2$, -CN, or a divalent C_{2-5}-alkylene radical wherein optionally one of the carbon units of said C_{2-5}-alkylene radical may be replaced by O, NH or N-C_{1-4}-alkyl; in particular $-(CH_2)_3-$, $-CH_2-C(NH_2)H-CH_2-$, $-CH_2-C(CN)H-CH_2-$, $-CH_2-C(CH_2-NH-CH_2)-CH_2-$, $-(CH_2)_4-$;

R^{2u} represents hydrogen or C_{1-4}-alkyl;

x represents 0 or 1;

z represents 0 or 1.

11. Compound according to any of the preceding claims, or any N-oxide, solvate, tautomer or stereoisomer thereof and/or any pharmaceutically acceptable salt of each of the foregoing, including mixtures thereof in all ratios, wherein

(a)

W^1 represents CH;

W^2 represents CH;

W^3 represents C-R^{W3};

W^4 represents CH;

R^{W3} represents methyl, 2-propyl, trifluoromethyl, methoxy, trifluoromethoxy, F, -CN, $-CH_2$-phenyl, $-CH_2$-(2-fluorophenyl), $-CH_2$-(3-fluorophenyl), $-CH_2$-(4-fluorophenyl);

or

(d)

W^1 represents CH;

W^2 represents N;

W^3 represents C-R^{W3};

W^4 represents CH;

R^{W3} represents methyl, 2-propyl, trifluoromethyl, methoxy, trifluoromethoxy, F, -CN, $-CH_2$-phenyl, $-CH_2$-(2-fluorophenyl), $-CH_2$-(3-fluorophenyl), $-CH_2$-(4-fluorophenyl);

or

(h)

W^1 represents CH;

W^2 represents CH;

W^3 represents C-R^{W3};

W^4 represents N;

R^{W3} represents methyl, 2-propyl, trifluoromethyl, methoxy, trifluoromethoxy, F, -CN, -CH_2-phenyl, -CH_2-(2-fluorophenyl), -CH_2-(3-fluorophenyl), -CH_2-(4-fluorophenyl);

and wherein further

Z^1 is CH;

Z^2 is CH

Z^3 is CH;

R^1 represents phenyl, 3-fluorophenyl, 4-fluorophenyl, 4-chlorophenyl, 4-methylphenyl, 4-ethylphenyl, 4-difluoromethylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-(1,1-difluorethyl)phenyl, 4-(2,2,2-trifluorethyl)phenyl, 4-(1-trifluoromethylcyclopropyl)-phen-1-yl, 4-cyclopentylphenyl, 4-ethoxyphenyl, 4-difluormethoxyphenyl, 4-trifluoromethoxyphenyl, 3-(trifluoromethyl)sulfanylphenyl, 4-(trifluoromethyl)sulfanylphenyl, 3-trifluoromethyl-4-methylphenyl, 2-fluoro-4-trifluoromethylphenyl, 3-fluoro-4-(n-propyl)phenyl, 2,3-dimethyl-4-methoxyphenyl, 6-fluoronaphth-2-yl; 5-trifluoromethylfuran-2-yl; 5-trifluoromethylthiophen-2-yl, 2-trifluoromethyl-1,3-thiazol-4-yl, 3-fluoropyridin-2-yl, 6-methylpyridin-3-yl, 6-methoxypyridin-3-yl, 3-ethylpyridin-2-yl, 6-ethylpyridin-3-yl, 4-difluoromethylpyridin-2-yl, 4-trifluoromethylpyridin-2-yl, 4-trifluoromethoxypyridin-2-yl, 4-cyanopyridin-2-yl, 5-trifluoromethylpyridin-2-yl, 6-trifluoromethylpyridin-2-yl, 6-trifluoromethylpyridin-3-yl (2-trifluoromethylpyridin-5-yl), 6-trifluoromethoxypyridin-3-yl (2-trifluoromethoxypyridin-5-yl), 5-cyanopyridin-2-yl, 5-cyanomethylpyridin-2-yl, 5-methanesulfonylpyridin-2-yl, 6-methoxypyridin-2-yl, 4-methylpyrimidin-2-yl, 4-ethylpyrimidin-2-yl, 4-methylsulfanylpyrimidin-2-yl, 5-cyclopropylpyrimidin-2-yl, 5-ethyl-pyrimidin-2-yl, 5-difluoromethylpyrimidin-2-yl, 5-trifluoromethylpyrimidin-2-yl, 5-cyanopyrimidin-2-yl, 5-cyano-3-fluoropyridin-2-yl, 5-cyano-6-

methylpyridin-2-yl, 3-fluoro-5-(trifluoromethyl)pyridin-2-yl, 5-oxo-5H,6H,7H-cyclopenta[b]pyridin-2-yl, 5,6,7,8-tetrahydroquinolin-2-yl, 5-oxo-5,6,7,8-tetrahydroquinolin-2-yl, 5H,6H,7H-cyclopenta[b]pyridin-2-yl, quinolin-2-yl, isoquinolin-3-yl, 6-methylquinolin-2-yl, 8-methoxyquinolin-4-yl, furo[3,2-b]pyridin-5-yl, quinazolin-2-yl, 6-fluoroquinazolin-2-yl, 1,5-naphthyridin-2-yl; 3-methylcyclobutyl, cyclopentyl, 3-methylcyclopentyl, 3,3-dimethylcyclopentyl, 3-trifluoromethyl-bicyclo[1.1.1]petan-1-yl, cyclohexyl, 4-methylcyclohexyl, 4-(trifluoromethyl)cyclohexyl, 4,4-difluorocyclohexyl, cyclohex-1-enyl, 2-oxocycloheptyl, 6,6-difluorospiro[3.3]heptan-2-yl, 1H-inden-2-yl; 4-benzenesulfonyl (phenylsulfonyl), 3-methylphenylsulfonyl, benzyl, 2-ethoxyphenylmethyl, 3-chlorophenylmethyl, 3-fluorophenylmethyl, 4-chlorophenylmethyl, 3-(pyrrolidine-1-yl)phenylmethyl, 3-methylphenylmethyl, 4-methylphenylmethyl, 3-ethylphenylmethyl, 3-(propan-2-yl)phenylmethyl, 3-tert-butylphenylmethyl, 3-(difluoromethoxy)phenylmethyl, 2-(difluoromethyl)phenylmethyl, 3-(difluoromethyl)phenylmethyl, 3-(trifluoromethyl)phenylmethyl, 4-(trifluoromethyl)phenyl]methyl, 2-(prop-2-yn-1-yloxy)phenylmethyl, 3-(1,3-thiazol-2-yl)phenylmethyl, 3-(trifluoromethyl)sulfanylphenylmethyl, 3-methanesulfonylphenylmethyl, 3-(dimethylamino)phenylmethyl, 3-(pyrrol-1-yl)phenylmethyl, 2-methyl-3-methoxyphenylmethyl, 3-trifluoromethyl-5-methylphenylmethyl, 2-methyl-3-(trifluoromethyl)phenylmethyl, 3-trifluoromethyl-4-fluorophenyl-methyl, 2-fluoro-5-(trifluoromethoxy)phenylmethyl, 2-methoxy-3-trifluoro-methoxyphenylmethyl, 2-fluoro-3-methoxyphenylmethyl, 2-fluoro-3-(trifluoromethyl)phenyl]methyl, 2-fluor-3-fluoromethoxyphenylmethyl, 2-trifluoromethoxy-5-fluorophenylmethyl, 2-fluor-5-chlor-phenylmethyl, 3-fluoro-5-methylphenyl)methyl, 3,5-difluorophenylmethyl, 5-fluoro-2-(trifluoromethyl)phenylmethyl, 3-fluoro-5-(trifluoromethyl)phenylmethyl, 2-chloro-3-(trifluoromethyl)phenylmethyl, naphthalin-1-ylmethyl, 5,6,7,8-tetrahydronaphthalen-1-ylmethyl, 2,3-dihydro-1-benzofuran-7-ylmethyl, 3,4-dihydro-2H-1-benzopyran-8-ylmethyl, 2-phenylethyl, 2-(2-methyl-phenyl)ethyl, 2-(2-methoxyphenyl)ethyl, 2-(3-methoxyphenyl)ethyl, 2-(4-

methoxyphenyl)ethyl, 2-(2-fluorophenyl)-ethyl, 2-(3-fluorophenyl)-ethyl, 2-(4-fluorophenyl)-ethyl, 2-(2-chlorophenyl)-ethyl, 2-(4-chlorophenyl)-ethyl, 2-(4-bromophenyl)-ethyl, 2-[4-(trifluoromethyl)phenyl]ethyl, 2-(2,4-difluorophenyl)ethyl, 2-(difluoromethoxy)-5-fluorophenylmethyl, 2-phenylpropyl, 3-phenylpropyl, 3-methyl-3-phenylbutyl, 2-(benzyl-oxy)ethyl; 5-ethylfuran-2-ylmethyl, 5-(trifluoromethyl)furan-2-ylmethyl, 4-(propan-2-yl)-1,3-thiazol-2-ylmethyl, 2-methyl-1,3-thiazol-4-ylmethyl, 2-trifluoromethyl-1,3-thiazol-4-ylmethyl, 1-ethylpyrazol-5-ylmethyl, 1-(2-propyl)pyrazol-5-ylmethyl, 1-ethylimidazol-5-ylmethyl, 1-ethylimidazol-2-ylmethyl, 1-propylimidazol-2-ylmethyl, 1-benzylimidazol-2-yl)methyl, 1-(2-methylpropyl)-1H-imidazol-5-ylmethyl, 5-tert-butyl-1,3-oxazol-2-ylmethyl, 3-fluoropyridin-2-ylmethyl, 2-methylpyridin-4-ylmethyl, 4-trifluoromethylpyridin-2-yl, 4-trifluoromethylpyridin-2-ylmethyl, 6-(fluoro-methyl)pyridin-2-ylmethyl, 6-trifluoromethylpyridin-2-yl, 2-(trifluoro-methyl)pyridin-4-ylmethyl, 4-methylpyrimidin-2-ylmethyl, 4-trifluoromethylpyridin-2-ylmethyl, 6-(fluoromethyl)pyridin-2-ylmethyl, 6-trifluoromethylpyridin-2-ylmethyl, 2-(trifluoromethyl)pyridin-4-ylmethyl, 4-methylpyrimidin-2-ylmethyl, 2-(thiophen-3-yl)ethyl, 5-trifluoromethylthiophen-2-ylmethyl, 1-methyl-1H-indol-6-yl)methyl, 1-benzofuran-3-ylmethyl, 1-benzothiophen-3-ylmethyl, 4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-ylmethyl, pyrazolo[1,5-a]pyridin-7-ylmethyl, pyrazolo[1,5-a]pyridin-3-ylmethyl, imidazo[1,2-a]pyridin-3-ylmethyl, 6-methylimidazo[1,2-a]pyridin-3-ylmethyl, imidazo[1,2-a]pyridin-5-ylmethyl, imidazo[1,5-a]pyridin-1-ylmethyl, imidazo[1,5-a]pyridin-3-ylmethyl, imidazo[1,5-a]pyridin-5-ylmethyl, pyrazolo[1,5-c]pyrimidin-3-ylmethyl, 3-(furan-2-yl)prop-2-en-1-yl; 3-trifluormethylcyclobutylmethyl, 3-fluoro-3-phenylcyclobutylmethyl, cyclohexylmethyl, 4-methylcyclo-hexylmethyl, 4-trifluoromethylcyclohexylmethyl, 4-methoxycyclohexyl-methyl, 4,4-dimethylcyclohexylmethyl, 4,4-difluorocyclohexylmethyl, 3-trifluoromethyl-bicyclo[1.1.1]pentan-1-ylmethyl, bicyclo[2.2.1]heptan-2-ylmethyl, bicyclo[2.2.2]octan-2-ylmethyl, bicyclo[2.2.1]hept-5-en-2-ylmethyl, 6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl]methyl; 3,3-

dimethyltetrahydrofuran-2-ylmethyl, 1,1-dioxothian-4-ylmethyl, 2-(thian-4-yl)ethyl; 2,2-dimethyl-4,4,4-trifluoropentyl, 4,4,4-trifluorobutyl, 4,4,4-trifluoro-3-methylbutyl, 3,3-dimethyl-4,4,4-trifluorobutyl, 3,3,3-trifluoroprop-1-yn-1-yl; and

R^2 represents -C(=O)-OH, -C(=O)-ONa, -C(=O)-OCH_3, -C(=O)-NH_2, -C(=O)-NH-CH_3, -C(=O)-NHCH_2CH_3, -C(=O)-NH$(CH_2)_2CH_3$, -C(=O)-N(H)-cyclopropyl, -C(=O)-N(H)-(1-hydroxymethyl)cyclobutan-1-yl, -C(=O)-N(H)-CH_2CH_2-OH, -C(=O)-N(H)-CH_2CH_2-OCH_3, -C(=O)-N(H)-$CH_2CH(CF_3)$-OH, -C(=O)-N(H)-$CH(CH_3)CH_2$-OH, -C(=O)-N(H)-$CH_2CH(CH_3)$-OH, -C(=O)-N(H)-$CH_2C(CH_3)_2$OH, -C(=O)-N(H)-$C(H)(CH_3)$-CH_2OH, -C(=O)-N(H)-$CH(CH_2CH_3)CH_2$-OH, -C(=O)-N(H)-$CH(CH(CH_3)_2)CH_2$-OH, -C(=O)-N(H)-$CH_2C(CH_3)_2$OH, -C(=O)-N(H)-CH(OH)CH_2-OH, -C(=O)-N(H)-C(H)(CH_2OH)-CH_2CH_2-O-CH_3, -C(=O)-N(H)-$C(CH_3)(CH_2OH)$-phenyl, -C(=O)-N(H)-CH(CH(CH_3)-OH)-phenyl, -C(=O)-N(H)-CH_2-1H-1-methylimidazol-2-yl, -C(=O)-N(H)-$(CH_2)_2$-1H-imidazol-1-yl, -C(=O)-N(H)-CH_2-pyridin-2-yl, -C(=O)-N(H)-CH_2-pyridin-3-yl, -C(=O)-N(H)-CH_2-pyridin-4-yl, -C(=O)-N(H)-CH_2-1,3-pyrimidin-4-yl, -C(=O)-N(H)-cyclopropyl, -C(=O)-N(H)-(1-hydroxymethyl)cyclobutan-1-yl, -C(=O)-N(H)-(4-hydroxy-tetrahydrofuran-3-yl), -C(=O)-3-hydroxy-pyrrolidin-1-yl, -C(=O)-3-hydroxy-piperidin-1-yl, -NH-C(=O)-$CH=CH_2$, -NH-C(=O)-CH_2Cl, -CH_2-NH-C(=O)-$CH=CH_2$, -CH_2-NH-C(=O)-CH_2Cl, -S(=O)-CH_3, -S(=O)$_2$-CH_3, -S(=O)$_2$-OH, -S(=O)$_2$-NH_2, -S(=O)(=NH)-$N(CH_3)_2$, -S(=O)(=N-CH_3)-$N(CH_3)_2$, -S(=O)(=N-CH_3)-OH, -S(=O)(=NH)-CH_3, -P(=O)$(OH)_2$, F, -CN; in particular -C(=O)-OH, -C(=O)-ONa, -C(=O)-NH_2, -C(=O)-NH-CH_3, -C(=O)-N(H)-CH_2CH_2-OH, -C(=O)-N(H)-$CH_2CH(CF_3)$-OH, -C(=O)-N(H)-$CH(CH_3)CH_2$-OH, -C(=O)-N(H)-$CH_2CH(CH_3)$-OH, -C(=O)-N(H)-$CH(CH_2CH_3)CH_2$-OH, -C(=O)-N(H)-$CH(CH(CH_3)_2)CH_2$-OH, -C(=O)-N(H)-$CH_2C(CH_3)_2$OH, -C(=O)-N(H)-CH(OH)CH_2-OH, -C(=O)-N(H)-C(H)(CH_2OH)-CH_2CH_2-O-CH_3, -C(=O)-N(H)-$C(CH_3)(CH_2OH)$-phenyl, -C(=O)-N(H)-CH(CH(CH_3)-OH)-phenyl, -C(=O)-N(H)-CH_2-1H-1-methylimidazol-2-yl, -C(=O)-N(H)-$(CH_2)_2$-1H-imidazol-1-yl, -C(=O)-N(H)-CH_2-pyridin-2-yl, -C(=O)-N(H)-CH_2-pyridin-3-

yl, -C(=O)-N(H)-CH_2-pyridin-4-yl, -C(=O)-N(H)-CH_2-1,3-pyrimidin-4-yl, -C(=O)-N(H)-cyclopropyl, -C(=O)-N(H)-(1-hydroxymethyl)cyclobutan-1-yl, -C(=O)-N(H)-(4-hydroxy-tetrahydrofuran-3-yl), -C(=O)-3-hydroxy-pyrrolidin-1-yl, -C(=O)-3-hydroxy-piperidin-1-yl; preferably -C(=O)-OH, -C(=O)-ONa, -C(=O)-NH-CH_3, -C(=O)-N(H)-cyclopropyl.

12. Compound according to any of claims 1 to 2, or any N-oxide, solvate, tautomer or stereoisomer thereof and/or any pharmaceutically acceptable salt of each of the foregoing, including mixtures thereof in all ratios, wherein

W^1 represents CH or N;

W^2 represents CH or N;

W^3 represents CH or N;

W^4 represents CH or N;

wherein either none of W^1, W^2, W^3 and W^4 represents N or only one of W^1, W^2, W^3 and W^4 represents N at the same time;

R^1 represents Ar^1, $Hetar^1$ or L^1-Ar^1; preferably Ar^1;

Ar^1 is a mono- or bicyclic aryl with 6 or 10 ring carbon atoms, wherein that aryl bears a least one substituent R^{B1} and optionally further substituents R^{B2} and/or R^{B3}; preferably phenyl which is monosubstituted with R^{B1};

$Hetar^1$ is a monocyclic heteroaryl with 5 or 6 ring atoms or a bicyclic heteroaryl with 9 or 10 ring atoms wherein 1, 2 or 3 of said ring atoms is/are a hetero atom(s) selected from N, O and/or S and the remaining are carbon atoms, wherein that heteroaryl bears at least one substituent R^{B1} and optionally further substituents R^{B2} and/or R^{B3}; preferably the heteroaryl is pyridyl and monosubstituted with R^{B1};

L^1 is -CH_2-;

R^{B1} represents a straight-chain or branched C_{1-6}-alkyl which is substituted with independently from each other 1, 2 or 3 halogen; preferably trifluoromethyl;

R^{B2}, R^{B3} represent independently from each other straight-chain or branched C_{1-6}-alkyl, which C_{1-6}-alkyl may be unsubstituted or monosubstituted with -CN or substituted with 1, 2 or 3 halogen, straight-

chain or branched C_{1-4}-alkoxy, which C_{1-4}-alkoxy may be unsubstituted or substituted with 1, 2 or 3 halogen, -O-CH_2-C≡CH, straight-chain or branched -S-C_{1-4}-alkyl, which -S-C_{1-4}-alkyl may be unsubstituted or substituted with 1, 2 or 3 halogen, F, Cl, Br, -CN, -N(C_{1-3}-alkyl)$_2$.

13. Compound according to claim 12, or any N-oxide, solvate, tautomer or stereoisomer thereof and/or any pharmaceutically acceptable salt of each of the foregoing, including mixtures thereof in all ratios, wherein

R^2 represents -C(=O)-OR^{2a} or $Hetcyc^X$; preferably -C(=O)-OR^{2a};

R^{2a} represents H, straight-chain or branched, unsubstituted or substituted C_{1-4}-alkyl or Cat; preferably H, methyl, ethyl or Cat;

Cat represents a monovalent cation selected from the group consisting of lithium (Li), sodium (Na) and potassium (K); preferably sodium;

$Hetcyc^X$ represents 1H-1,2,3,4-tetrazol-5-yl, 2H-1,2,3,4-tetrazol-5-yl, 2-methyl-2H-1,2,3,4-tetrazol-5-yl, 5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl (2H-1,2,4-oxadiazol-5-on-3-yl), 5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl (4H-1,2,4-oxadiazol-5-on-3-yl), 3-bromo-4,5-dihydro-1,2-oxazol-5-yl, 3-chloro-4,5-dihydro-1,2-oxazol-5-yl, 3-(1H-1,2,3-triazol-1-yl)-4,5-dihydro-1,2-oxazol-5-yl, 3-(2H-1,2,3-triazol-2-yl)-4,5-dihydro-1,2-oxazol-5-yl, 3-(pyrimidin-5-yloxy)-4,5-dihydro-1,2-oxazol-5-yl, 3-hydroxy-oxetan-3-yl, 5-hydroxy-4H-pyran-4-on-2-yl, 3,3-difluoropyrrolidin-2-on-4-yl, 3,3-difluoropyrrolidin-2-on-5-yl, 3,3-difluoro-2,3-dihydro-1H-pyrrol-2-on-4-yl, 3,3-difluoro-2,3-dihydro-1H-pyrrol-2-on-5-yl.

14. Compound according to claim 12, or any N-oxide, solvate, tautomer or stereoisomer thereof and/or any pharmaceutically acceptable salt of each of the foregoing, including mixtures thereof in all ratios, wherein

R^2 represents -C(=O)-$NR^{2b}R^{2c}$; and wherein

(a)

R^{2b} represents hydrogen,

R^{2c} represents hydrogen; straight-chain or branched C_{1-8}-alkyl which may be unsubstituted or substituted with R^{E1}, R^{E2}, R^{E3}, R^{E4} and/or R^{E5} which may be the same or different; Cyc^2 or $Hetcyc^2$, wherein

R^{E1}, R^{E2}, R^{E3}, R^{E4} and/or R^{E5} represent independently from each other halogen, in particular F; $-NR^{Ea}R^{Eb}$, -OH, OR^{Ec}, Ar^E, $Hetar^E$, Cyc^E, $Hetcyc^E$;

Ar^E is a mono- or bicyclic aryl with 6 or 10 ring carbon atoms, wherein that aryl may be unsubstituted or substituted with substituents R^{F1}, R^{F2} and/or R^{F3} which may be the same or different; preferably phenyl or naphthalenyl, in particular phenyl;

$Hetar^E$ is a monocyclic heteroaryl with 5 or 6 ring atoms or a bicyclic heteroaryl with 9 or 10 ring atoms wherein 1, 2, 3, or 4 of said ring atoms is/are a hetero atom(s) selected from N, O and/or S and the remaining are carbon atoms, wherein that heteroaryl may be unsubstituted or substituted with substituents R^{F1}, R^{F2} and/or R^{F3} which may be the same or different; in particular the heteroaryl is a moncyclic heteroaryl with 5 or 6 ring atoms which may be unsubstituted or substituted with substituents R^{F1} and/or R^{F2} which may be the same or different; preferably the heteroaryl is selected from the group consisting of imidazolyl, 1H-imidazol-1-yl, 1H-imidazol-2-yl, each of which unsubstituted or monosubstituted with C_{1-4}-alkyl; pyridyl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, each of which may be unsubstituted or monosubstituted with -F; pyrimidinyl, pyrimidin-2-yl, pyrimidin-3-yl, pyrimidin-4-yl; pyrazinyl, pyrazin-2-yl, pyrimidin-5-yl; pyrazinyl, pyrazin-2-yl pyridazinyl, pyridazin-3-yl; furanyl, pyrrolyl, pyrazolyl, oxazolyl, isoxazolyl; oxadiazolyl, triazolyl, thiazolyl, isothiazolyl;

Cyc^E is a saturated or partially unsaturated, mono- or bicyclic carbocycle with 3, 4, 5, 6, 7 or 8 ring carbon atoms, wherein that carbocycle may be unsubstituted or substituted with R^{G1} and/or R^{G2} which may be the same or different: in particular, a saturated monocyclic carbocycle with 3, 4, 5, or 6 ring carbon atoms, wherein that carbocycle may be unsubstituted or substituted with R^{G1} and/or R^{G2} which may be the same or different; preferably cyclopropyl, cyclobutyl, cyclohexenyl;

$Hetcyc^E$ is a saturated or partially unsaturated, monocyclic heterocycle with 4, 5 or 6 ring atoms wherein 1 or 2 of said ring atoms is/are a hetero atom(s) selected from N, O and/or S and the remaining are carbon atoms, wherein that heterocycle may be unsubstituted or substituted with R^{G1} and/or R^{G2} which may be the same or different; in particular a saturated monocyclic heterocycle with 5 or 6 ring atoms wherein 1 or 2 of said ring atoms is/are a hetero atom(s) selected from N and/or O and the remaining are carbon atoms, wherein that heterocycle may be unsubstituted or monosubstituted with R^{G1}; preferably tetrahydrofuranyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl each of which may be unsubstituted or monosubstituted with -OH; pyrrolindinyl, pyrrolindin-1-yl, pyrrolindin-2-yl, pyrrolindin-3-yl, each of which may be unsubstituted or monosubstituted with -OH; piperidinyl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, each of which may be unsubstituted or monosubstituted with -OH; morpholinyl, morpholin-1-yl, morpholin-2-yl each of which may be unsubstituted or mono-substituted with methyl; 1,4-dioxanyl; dihydropyranyl, tetrahydropyranyl, tetrahydropyran-3-yl;

R^{Ea}, R^{Eb} represent independently from each other H, C_{1-4}-alkyl, -C(=O)-OC_{1-4}-alkyl; in particular both represent H or one represents H and the other represents C(=O)-O-tert.-butyl;

R^{Ec} represents H or C_{1-4}-alkyl, in particular H or methyl;

R^{F1}, R^{F2} and/or R^{F3} represent independently from each other straight-chain or branched C_{1-6}-alkyl, which C_{1-6}-alkyl may be unsubstituted or monosubstituted with -CN, OH, -O-C_{1-4}-alkyl or substituted with 1, 2 or 3 halogen, straight-chain or branched C_{1-4}-alkoxy, which C_{1-4}-alkoxy may be unsubstituted or substituted with 1, 2 or 3 halogen, straight-chain or branched -S-C_{1-4}-alkyl, which -S-C_{1-4}-alkyl may be unsubstituted or substituted with 1, 2 or 3 halogen, F, Cl, Br, -CN, -S(=O)-C_{1-3}-alkyl, $S(=O)_2$-C_{1-3}-alkyl, $-NH_2$, -NH(C_{1-3}-alkyl), -N(C_{1-3}-alkyl)$_2$, -OH; in particular methyl, hydroxymethyl, methoxymethyl, F, cyclopropyl, cyclobutyl; preferably only one of R^{F1}, R^{F2} and R^{F3} is present and represents methyl or F;

and/or two of R^{F1}, R^{F2}, R^{F3} which are attached to two different ring atoms of that aryl or heteroaryl form a divalent C_{1-6}-alkylene radical wherein optionally one or two non-adjacent carbon units of that alkylene radical may be replaced by independently from each other O, NH, N-C_{1-4}-alkyl, in particular $–(CH_2)_4$-, -CH_2-O-$(CH_2)_2$-;

R^{G1} and/or R^{G2} represent independently from each other halogen, hydroxy, unsubstituted or substituted C_{1-6}-aliphatic, in particular C_{1-4}-alkyl optionally substituted with OH, C_{1-6}-aliphatoxy, in particular -O-C_{1-4}-alkyl, -C(=O)-O-C_{1-4}-alkyl, $Hetar^{Y2}$, -CH_2-$Hetar^{Y2}$, $Hetcyc^{Y2}$, in particular hydroxy; preferably only one of R^{G1} and R^{G2} is present and represents hydroxy;

and/or R^{G1} and R^{G2} which are attached to the same ring atom of that carbocycle or heterocycle form a divalent C_{2-6}-alkylene radical wherein optionally one or two non-adjacent carbon units of that alkylene radical may be replaced by independently from each other O, NH, N-C_{1-4}-alkyl, and wherein that alkylene radical may optionally be substituted with OH, C_{1-4}-alkyl or -O-C_{1-4}-alkyl, in particular $–(CH_2)_2$-O-CH_2-, $–(CH_2)_2$-O-$(CH_2)_2$-;

and/or R^{G1} and R^{G2} which are attached to two different ring atoms of that carbocycle or heterocycle form a divalent C_{1-6}-alkylene radical wherein optionally one or two non-adjacent carbon units of that alkylene radical may be replaced by independently from each other O, NH, N-C_{1-4}-alkyl, in particular -CH_2-;

Cyc^2 is a saturated monocyclic carbocycle with 3, 4, 5, 6 or 7 ring carbon atoms, wherein that carbocycle may be unsubstituted or substituted independently from each other with R^{D6}, R^{D7}, R^{D8}, R^{D9} and/or R^{D10} wherein that carbocycle may optionally be fused to Ar^Z or $Hetar^Z$ via 2 adjacent ring atoms and wherein that fused carbocycle may optionally further be substituted with independently from each other R^{C1}, R^{C2} and/or R^{C3};

$Hetcyc^2$ is a saturated monocyclic heterocycle with 4, 5 or 6 ring atoms wherein 1 or 2 of said ring atoms is/are a hetero atom(s) selected from

N, O and/or S and the remaining are carbon atoms, wherein that heterocycle may be unsubstituted or substituted independently from each other with R^{D6}, R^{D7}, R^{D8}, R^{D9} and/or R^{D10} wherein that heterocycle may optionally be fused to Ar^Z or $Hetar^Z$ and wherein that fused heterocycle may optionally further be substituted with independently from each other R^{C1}, R^{C2} and/or R^{C3};

R^{C1}, R^{C2}, R^{C3} independently from each other represent C_{1-4}-alkyl;

R^{D6}, R^{D7}, R^{D8}, R^{D9}, R^{D10} represent independently from each other halogen, in particular F; hydroxy; C_{1-4}-alkyl optionally substituted with -OH and/or halogen, in particular methyl, hydroxymethyl, 2-fluorethyl; -O-C_{1-4}-alkyl, in particular methoxy, ethoxy; $Hetar^{Y1}$, -CH_2-$Hetar^{Y1}$, Cyc^{Y1}, $Hetcyc^{Y1}$, -CH_2-$Hetcyc^{Y1}$;

and/or two of R^{D6}, R^{D7}, R^{D8}, R^{D9}, R^{D10} which are attached to the same ring atom of that carbocycle or heterocycle form a divalent C_{2-6}-alkylene radical wherein optionally one or two non-adjacent carbon units of that alkylene radical may be replaced by independently from each other O, NH, N-C_{1-4}-alkyl, and wherein that alkylene radical may optionally be substituted with OH, C_{1-4}-alkyl or -O-C_{1-4}-alkyl, in particular –$(CH_2)_3$-, –CH_2-$CH(OC_2H_5)$-CH_2-, –$(CH_2)_2$-O-$(CH_2)_2$-;

and/or two of R^{D6}, R^{D7}, R^{D8}, R^{D9}, R^{D10} which are attached to two different ring atoms of that carbocycle or heterocycle form a divalent C_{1-6}-alkylene radical wherein optionally one or two non-adjacent carbon units of that alkylene radical may be replaced by independently from each other O, NH, N-C_{1-4}-alkyl, in particular -CH_2-, –$(CH_2)_3$-, -O-$(CH_2)_2$-, -O-$(CH_2)_3$-;

Ar^Z is benzo;

$Hetar^{Y1}$ is a 5 or 6 membered monocyclic heteroaryl wherein 1, 2, 3, 4 ring atoms are hetero atoms selected from N, O and/or S and the remaining are carbon atoms, wherein that heteroaryl may be unsubstituted or substituted with F, C_{1-4}-alkyl which may optionally be substituted with OH; in particular pyrrolyl, thiophenyl, pyrazolyl, methylpyrazolyl, imidazolyl, methylimidazolyl, triazolyl, oxadiazolyl, methyloxadiazolyl, pyrdinyl, fluoropyrdinyl, methylpyridinyl, pyrimidinyl, methylpyrimidinyl;

$Hetar^{Y2}$ is a 5 or 6 membered monocyclic heteroaryl wherein 1, 2, 3, 4 ring atoms are hetero atoms selected from N, O and/or S and the remaining are carbon atoms, wherein that heteroaryl may be unsubstituted or substituted with halogen, C_{1-4}-alkyl which may optionally be substituted with OH; in particular pyrrolyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, hydroxymethyloxazolyl;

$Hetar^{Z}$ is pyrrole, N-methyl-pyrrole, pyrazole, imidazole, triazole;

Cyc^{Y1} is a saturated monocyclic carbocycle with 3, 4, 5, 6 or 7 ring carbon atoms, wherein that carbocycle may be unsubstituted or substituted with halogen, OH, C_{1-4}-alkyl, in particular cyclopropyl;

$Hetcyc^{Y1}$ is a saturated or partially unsaturated monocyclic heterocycle with 5 or 6 ring atoms wherein 1 or 2 of said ring atoms are heteroatoms selected from N, O, and/or S and the remaining are carbon atoms; in particular tetrahydrofuranyl;

$Hetcyc^{Y2}$ is a saturated or partially unsaturated monocyclic heterocycle with 5 or 6 ring atoms wherein 1 or 2 of said ring atoms are heteroatoms selected from N, O, and/or S and the remaining are carbon atoms; in particular tetrahydrofuranyl, morpholinyl, tetrahydropyranyl;

or

(b)

R^{2b} and R^{2c} form together with the nitrogen atom to which they are attached to a saturated or partially unsaturated heterocycle with 3, 4, 5, 6, 7 ring atoms wherein 1 of said ring atoms is said nitrogen atom and no or one further ring atom is a hetero atom selected from N, O or S and the remaining are carbon atoms which heterocycle is optionally substituted with independently from each other R^{Y1}, R^{Y2}, R^{Y3}, R^{Y4} and/or R^{Y5}; wherein that heterocycle may optionally be fused with $Hetar^{Z}$; and wherein that heterocycle is preferably selected from the group consisting of: azetidine, pyrrolidine, piperidine, piperazine, morpholine

R^{Y1}, R^{Y2}, R^{Y3}, R^{Y4}, R^{Y5} represent independently from each other halogen, in particular F; $-NH_2$, $-N(H)-C_{1-4}$-alkyl, $-N(H)-C(=O)-O-C_{1-4}$-alkyl, $-N(C_{1-4}$-alkyl$)_2$; -OH; C_{1-4}-alkyl optionally substituted with -OH, $-O-C_{1-4}$-alkyl, -O-

C_{3-7}-cycloalkyl, -O-CH_2-C_{3-7}-cycloalkyl, in particular methyl, -CH_2OH, -$(CH_2)_2OH$, -$(CH_2)_3OH$, -CH_2OCH_3, -$(CH_2)_2OCH_3$, cyclopropylmethoxy; -O-C_{1-4}-alkyl, in particular methoxy; $Hetar^{Y2}$; -CH_2-$Hetar^{Y2}$; $Hetcyc^{Y2}$;

and/or two of R^{Y1}, R^{Y2}, R^{Y3}, R^{Y4}, R^{Y5} which are attached to the same ring atom of that heterocycle form a divalent C_{2-6}-alkylene radical wherein optionally one or two non-adjacent carbon units of that alkylene radical may be replaced by independently from each other O, NH, N-C_{1-4}-alkyl, in particular –$(CH_2)_4$-, –$(CH_2)_2$-O-$(CH_2)_2$-, –$(CH_2)_2$-O-$(CH_2)_3$-;

and/or two of R^{Y1}, R^{Y2}, R^{Y3}, R^{Y4}, R^{Y5} which are attached to two different ring atoms of that heterocycle form a divalent C_{1-6}-alkylene radical wherein optionally one or two non-adjacent carbon units of that alkylene radical may be replaced by independently from each other O, NH, N-C_{1-4}-alkyl, in particular –$(CH_2)_4$-;

$Hetar^{Y2}$ is a 5 or 6 membered monocyclic heteroaryl wherein 1, 2, 3, 4 ring atoms are hetero atoms selected from N, O and/or S and the remaining are carbon atoms, wherein that heteroaryl may be unsubstituted or substituted with halogen, C_{1-4}-alkyl which may optionally be substituted with OH; in particular pyrrolyl, thiophenyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, hydroxymethyloxazolyl, pyrimidinyl;

$Hetar^{Z}$ is pyrrole, N-methyl-pyrrole, pyrazole, imidazole, triazole;

$Hetcyc^{Y2}$ is a saturated or partially unsaturated monocyclic heterocycle with 5 or 6 ring atoms wherein 1 or 2 of said ring atoms are heteroatoms selected from N, O, and/or S and the remaining are carbon atoms; in particular tetrahydrofuranyl, morpholinyl, tetrahydropyranyl;

or

(c)

R^{2b} represents a straight-chain of branched C_{1-4}-alkyl optionally substituted with OH; in particular methyl, 2-hydroxyethyl;

and

R^{2c} represents Cyc^2, $Hetcyc^2$ or straight-chain or branched C_{1-8}-alkyl which may be unsubstituted or substituted with independently from each other R^{E1}, R^{E2}, R^{E3}, R^{E4} and/or R^{E5} which may be the same or different; and

wherein Cyc^2, $Hetcyc^2$, R^{E1}, R^{E2}, R^{E3}, R^{E4} and R^{E5} are as defined above under (a).

15. Compound according to any of claims 12 or 14, or any N-oxide, solvate, tautomer or stereoisomer thereof and/or any pharmaceutically acceptable salt of each of the foregoing, including mixtures thereof in all ratios, wherein

R^2 represents $-C(=O)-NR^{2b}R^{2c}$; and wherein

(a)

R^{2b} represents hydrogen,

R^{2c} represents hydrogen; straight-chain or branched C_{1-8}-alkyl which may be unsubstituted or substituted with R^{E1}, R^{E2}, R^{E3}, R^{E4} and/or R^{E5} which may be the same or different; Cyc^2 or $Hetcyc^2$, wherein

R^{E1}, R^{E2}, R^{E3}, R^{E4} and/or R^{E5} represent independently from each other halogen, in particular F; $-NR^{Ea}R^{Eb}$, -OH, OR^{Ec}, Ar^E, $Hetar^E$, Cyc^E, $Hetcyc^E$;

Ar^E is a mono- or bicyclic aryl with 6 or 10 ring carbon atoms, wherein that aryl may be unsubstituted or substituted with substituents R^{F1}, R^{F2} and/or R^{F3} which may be the same or different; preferably phenyl or naphthalenyl, in particular phenyl;

$Hetar^E$ is a monocyclic heteroaryl with 5 or 6 ring atoms or a bicyclic heteroaryl with 9 or 10 ring atoms wherein 1, 2, 3, or 4 of said ring atoms is/are a hetero atom(s) selected from N, O and/or S and the remaining are carbon atoms, wherein that heteroaryl may be unsubstituted or substituted with substituents R^{F1}, R^{F2} and/or R^{F3} which may be the same or different; in particular the heteroaryl is a moncyclic heteroaryl with 5 or 6 ring atoms which may be unsubstituted or substituted with substituents R^{F1} and/or R^{F2} which may be the same or different; preferably the heteroaryl is selected from the group consisting of imidazolyl, 1H-imidazol-1-yl, 1H-imidazol-2-yl, each of which unsubstituted or monosubstituted with C_{1-4}-alkyl; pyridyl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, each of which may be unsubstituted or monosubstituted with -F; pyrimidinyl, pyrimidin-2-yl, pyrimidin-3-yl, pyrimidin-4-yl; pyrazinyl, pyrazin-2-yl;

Cyc^E is a saturated or partially unsaturated, mono- or bicyclic carbocycle with 3, 4, 5, 6, 7 or 8 ring carbon atoms, wherein that carbocycle may be unsubstituted or substituted with R^{G1} and/or R^{G2} which may be the same or different: in particular, a saturated monocyclic carbocycle with 3, 4, 5, or 6 ring carbon atoms, wherein that carbocycle may be unsubstituted or substituted with R^{G1} and/or R^{G2} which may be the same or different; preferably cyclobutyl;

$Hetcyc^E$ is a saturated or partially unsaturated, monocyclic heterocycle with 5 or 6 ring atoms wherein 1 or 2 of said ring atoms is/are a hetero atom(s) selected from N, O and/or S and the remaining are carbon atoms, wherein that heterocycle may be unsubstituted or substituted with R^{G1} and/or R^{G2} which may be the same or different; in particular a saturated monocyclic heterocycle with 5 or 6 ring atoms wherein 1 or 2 of said ring atoms is/are a hetero atom(s) selected from N and/or O and the remaining are carbon atoms, wherein that heterocycle may be unsubstituted or monosubstituted with R^{G1}; preferably tetrahydrofuranyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl each of which may be unsubstituted or monosubstituted with -OH; pyrrolindinyl, pyrrolindin-1-yl, pyrrolindin-2-yl, pyrrolindin-3-yl, each of which may be unsubstituted or monosubstituted with -OH; piperidinyl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, each of which may be unsubstituted or monosubstituted with -OH; morpholinyl, morpholin-1-yl, morpholin-2-yl;

R^{Ea}, R^{Eb} represent independently from each other H, C_{1-4}-alkyl, -C(=O)-OC_{1-4}-alkyl; in particular both represent H or one represents H and the other represents C(=O)-O-tert.-butyl;

R^{Ec} represents H or C_{1-4}-alkyl, in particular H or methyl;

R^{F1}, R^{F2} and/or R^{F3} represent independently from each other straight-chain or branched C_{1-6}-alkyl, which C_{1-6}-alkyl may be unsubstituted or monosubstituted with -CN or substituted with 1, 2 or 3 halogen, straight-chain or branched C_{1-4}-alkoxy, which C_{1-4}-alkoxy may be unsubstituted or substituted with 1, 2 or 3 halogen, straight-chain or branched -S-C_{1-4}-alkyl, which -S-C_{1-4}-alkyl may be unsubstituted or substituted with 1, 2 or

3 halogen, F, Cl, Br, -CN, $-NH_2$, $-NH(C_{1-3}\text{-alkyl})$, $-N(C_{1-3}\text{-alkyl})_2$, -OH; in particular methyl, F; preferably only one of R^{F1}, R^{F2} and R^{F3} is present and represents methyl or F;

R^{G1} and/or R^{G2} represent independently from each other halogen, hydroxy, unsubstituted or substituted C_{1-6}-aliphatic, C_{1-6}-aliphatoxy, in particular hydroxy; preferably only one of R^{G1} and R^{G2} is present and represents hydroxy;

Cyc^2 is a saturated monocyclic carbocycle with 3, 4, 5, 6 or 7 ring carbon atoms, wherein that carbocycle may be unsubstituted or mono-substituted with R^{D6}, wherein

R^{D6} is C_{1-4}-alkyl which is unsubstituted or mono-substituted with -OH, in particular $-CH_2OH$;

in particular Cyc^2 is cyclopropyl, cyclobutyl or 1-hydroxymethyl-cyclobutyl;

$Hetcyc^2$ is a saturated monocyclic heterocycle with 5 or 6 ring atoms wherein 1 or 2 of said ring atoms is/are a hetero atom(s) selected from N, O and/or S and the remaining are carbon atoms, wherein that heterocycle may be unsubstituted or mono-substituted with hydroxy; in particular tetrahydrofuranyl or hydroxytetrahydrofuranyl; preferably 4-hydroxytetrahydrofuran-3-yl;

or

(b)

R^{2b} and R^{2c} form together with the nitrogen atom to which they are attached to a 3-hydroxypyrrolidinyl, 2-methyl-3-hydroxypyrrolidinyl or 3-hydroxypiperidinyl ring.

16. Compound, which is selected from the group consisting of compounds of Table 1, or any N-oxide, solvate, tautomer or stereoisomer thereof and/or any pharmaceutically acceptable salt of each of the foregoing, including mixtures thereof in all ratios.

17. Compound according to any of claims 1 to 16, or any N-oxide, solvate, tautomer or stereoisomer thereof and/or the pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, for use as a medicament.

18. Compound according to any of claims 1 to 16, or any N-oxide, solvate, tautomer or stereoisomer thereof and/or the pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, for use in the prevention and/or treatment of a medical condition or disease selected from the group consisting of: cancer, in particular tumors including solid tumors, of breast cancer, lung cancer, liver cancer, ovarian cancer, squamous cancer, renal cancer, gastric cancer, medulloblastoma, colon cancer, pancreatic cancer; cardiovascular diseases and fibrosis, in particular, liver fibrosis.

19. A pharmaceutical composition comprising at least one compound according to any one of claims 1 to 16, or any N-oxide, solvate, tautomer or stereoisomer thereof and/or the pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, as active ingredient, together with a pharmaceutically acceptable carrier.

20. The pharmaceutical composition according to claim 19 that further comprises a second active ingredient or any N-oxide, solvate, tautomer or stereoisomer thereof and/or the pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, wherein that second active ingredient is other than a compound of formula I-A as defined in any one of claims 1 to 16.


21. Set (kit) comprising separate packs of

a) an effective amount of a compound of formula I-A according to any one of claims 1 to 16, or any N-oxide, solvate, tautomer or stereoisomer thereof and/or the pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios; and

b) an effective amount of a further active ingredient that further active ingredient not being a compound of formula I-A as defined in any one of claims 1 to 16.

22. Process for manufacturing a compound according to any one of claims 1 to 16, or any N-oxide, solvate, tautomer or stereoisomer thereof and/or the pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, the process being characterized in that either

(a) a compound of formula II-A-a



II-A-a,

wherein Z^1, Z^2, Z^3, W^1. W^2, W^3, W^4 and R^2 are as defined for the compound of formula I-A in any of claims 1 to 16 wherein R^2 is not -C(=O)-OH or -C(=O)-OCat;

is either

(a) (1) reacted with a compound of formula III

R^1-Hal


III,

wherein R^1 is as defined for the compound of formula I-A in any of claims 1 to 16 and Hal represents Cl, Br or I,

in a C-N cross coupling reaction under suitable reaction conditions;

or

(a) (2) is first converted into the tricyclic compound of formula IV-A




IV-A

in a C-N cross coupling reaction under suitable reaction conditions; and
then reacted with a compound of formula III

R^1-Hal

III,

in another C-N cross coupling reaction under suitable reaction conditions;
to provide
(a) (3) a compound of formula I or I-A as defined in any of claims 1 to 16; and
optionally
(a) (4) if in the compound of formula I-A R^2 is -C(=O)-OR^{2a} with R^{2a} being unsubstituted or substituted C_{1-8}-aliphatic, then this compound of formula I-A is subjected to a saponification reaction under suitable conditions to provide the respective compound of formula I-A with R^2 being -C(=O)-OH or -C(=O)-OCat;
or
(b) a compound of formula II-A-b



II-A-b,

wherein Z^1, Z^2, Z^3, W^1. W^2, W^3, W^4 and R^2 are as defined for the compound of formula I-A in any of claims 1 to 16 wherein R^2 is not -C(=O)-OH or -C(=O)-OCat;
(b) (1) is reacted with a compound of formula V

R^1-NH_2

V,

wherein R^1 is as defined for the compound of formula I-A in any of claims 1 to 16,
in a C-N cross coupling reaction under suitable reaction conditions to provide a compound of formula I-A as defined in any of claims 1 to 16; and
optionally

(b) (2) if in the compound of formula I-A R^2 is -C(=O)-OR^{2a} with R^{2a} being unsubstituted or substituted C_{1-8}-aliphatic, then this compound of formula I-A is subjected to a saponification reaction under suitable conditions to provide the respective compound of formula I-A with R^2 being -C(=O)-OH or -C(=O)-OCat.